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Abstract 
 
 Androgen receptor (AR) is a hormone-responsive transcription factor central to prostate 
cancer (PCa) onset and progression. Therapies targeting AR signaling are initially successful, yet 
acquired resistance is a major problem. This thesis examines how AR cooperates with common 
pathways of oncogene activation and tumor suppressor loss in PCa. 
 Recurrent genomic rearrangements in PCa fuse the coding region of ETS family 
transcription factors with androgen-responsive regulatory elements, driving high expression in 
half of all tumors. Oncogenic ETS proteins promote early neoplasia and invasion in model 
systems, yet their prognostic value is unclear. Loss of the tumor suppressor PTEN occurs 
frequently in PCa, is associated with poor prognosis and treatment resistance, and causes 
neoplasia in model systems. 
 To probe the interaction of the androgen axis with oncogenic ETS expression and PTEN 
loss, mice expressing a stronger or weaker humanized AR allele were crossed with mice 
overexpressing the less-studied ETS factor ETV1 or lacking one Pten allele. While AR strength 
did not affect ETV1-driven neoplasia, global gene expression analysis by RNA-seq revealed that 
ETV1 strongly antagonized AR transcriptional activity. Repressed targets included tumor 
suppressors and prostate differentiation genes such as Nkx3-1 and Hoxb13. This suggests that the 
ETV1 oncogenic program primes the prostate for disease progression following additional 
genetic lesions. Indeed, the combination of ETV1 overexpression and Pten reduction promoted 
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progression of disease, and this was more frequent with a stronger AR allele. RNA-seq showed 
that ETV1 antagonism of AR was abrogated in neoplasia with reduced Pten, but in tumors AR 
was again repressed. Comparison to patient data revealed known and novel PCa-associated genes 
with potential ETV1 regulation. 
 Benign human prostate cells, as well as PCa cells harboring ETV1 overexpression with or 
without PTEN loss, were used to model PCa progression in vitro. In malignant cells ETV1 
consistently antagonized the same key AR targets as in mouse tissue, but in benign cells 
cooperation as well as repression was shown. These experiments highlight the interdependent 
relationships of the androgen axis, oncogene activation and tumor suppressor loss in PCa, 
revealing multiple pathways that should be considered simultaneously in future research and 
therapy. 
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Chapter 1 
 
Introduction 
 Prostate cancer (PCa) is one of the most common cancers in Western countries, leading 
to the deaths of 27,000 men per year in the United States. The prostate is a hormone-responsive 
tissue, and prostate differentiation and PCa progression are driven by the androgen receptor (AR) 
(Heinlein and Chang, 2004). Thus, standard therapeutic strategies for metastatic PCa include 
targeting AR via ablation of circulating androgens or directly with AR inhibitors 
(antiandrogens). Unfortunately, despite initial positive response, metastatic PCa evades current 
AR-targeted therapies and often recurs as fatal castration-resistant prostate cancer (CRPC). In 
this state, the tumor is still dependent on AR despite ongoing androgen ablation. AR overcomes 
therapeutic inhibition by a variety of means including gene mutation, amplification and cofactor 
dysregulation, allowing a hypersensitive response to low androgen levels so that AR signaling 
persists in CRPC (Feldman and Feldman, 2001). This thesis probes the interaction between AR 
and the molecular pathways most commonly disrupted in PCa progression. 
 A significant difficulty in clinical management of PCa is accurately identifying the subset 
of early-stage patients who will develop metastatic disease. The majority of primary prostate 
tumors occur late in life, are slow growing, and will not present substantial health problems 
during the patient's lifetime (Waterbor and Bueschen, 1995). While radiation or prostatectomy 
can cure localized disease, improved biomarkers could supplement clinicopathological 
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parameters to best identify the patients who will benefit from these interventions. For patients 
whose tumors do metastasize, novel therapeutic strategies are needed to combat resistance. 
Alternative targets or more individually stratified treatments would help to achieve maximum 
therapeutic benefit. 
 AR signaling is central to prostate differentiation and PCa progression, and must be 
considered when asking how additional disruptions promote oncogenesis. AR transcriptional 
strength varies inversely with the length of an N-terminal polyglutamine tract (Q-tract) whose 
length is polymorphic in the population. While not a risk factor for PCa by itself, varying AR 
strength has previously been shown to affect male physiology in humans and mice, as well as 
PCa initiation, progression and treatment response in a transgenic mouse model (Robins, 2011). 
In this thesis, AR variation will be incorporated into in vivo models of common somatic 
alterations in PCa to explore the impact of subtle differences in the AR axis. 
 Recurrent oncogene activation and/or tumor suppressor loss occur in the majority of PCa 
patients. Genomic rearrangements that fuse coding regions of members of the ETS family of cell 
cycle transcription factors to androgen-responsive regulatory regions, driving ETS gene 
overexpression, are seen in over half of prostate tumors in PSA-screened Caucasian cohorts 
(Rubin et al., 2011; Tomlins et al., 2005). These gene fusions occur early in patients, and in 
model systems ETS overexpression induces invasion, early neoplasia and altered AR signaling. 
Partial or complete loss of the tumor suppressor PTEN occurs in greater than 50% of PCa as 
well. PTEN loss promotes PCa in animal models in a dose-dependent manner and is associated 
with altered AR activity and progression to CRPC (Shen and Abate-Shen, 2010). 
 The aim of this thesis is to develop a more complete scientific understanding of the 
interaction of three commonly disrupted pathways described above: AR variation, ETS gene 
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fusion and PTEN loss. This understanding may inform patient stratification and help distinguish 
indolent from lethal tumors. Furthermore, examination of the molecular outcomes via 
downstream gene expression patterns may suggest potential biomarkers or new therapeutic 
targets. 
 
Androgens and the Androgen Receptor 
 The prostate is a hormone-responsive tissue. Prostate tumors and metastases continue to 
be hormone dependent throughout most stages of progression, specifically requiring androgens 
acting via the AR. AR is a steroid hormone-responsive transcription factor in the nuclear 
receptor superfamily. The 110 kDa AR protein consists of an N-terminal transactivation domain 
(NTD), a DNA binding domain (DBD) consisting of two zinc fingers, a hinge region and a C-
terminal ligand binding domain (LBD) that also has transactivation and coregulator recruitment 
functions, similar to other nuclear receptors (Figure 1.1) (Robins, 2005, 2011).  
 Testosterone can bind and activate AR, but it is not the usual or most potent ligand 
(Grino et al., 1990). After circulating testosterone enters an androgen-responsive cell, it is 
converted to the more potent ligand dihydrotestosterone (DHT) by the 5α-reductase enzyme 
(SRD5A2). DHT then binds the LBD of AR, inducing a conformational change. This 
conformational change releases AR from its cytoplasmic chaperone heat-shock protein 90 
(HSP90), which holds AR in a ligand-receptive conformation as well as sequestering it in the 
cytoplasm in the absence of ligand (Fang et al., 1996). AR has a nuclear localization signal 
(NLS) in the hinge region beyond the DBD, and a cytoplasmic localization signal (CLS) in the 
LBD. Together, these motifs promote nuclear translocation of ligand-bound AR and cytoplasmic 
translocation of unliganded AR (Jenster et al., 1993; Saporita et al., 2003). 
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 The repositioning of helices 3, 4 and 12 within the LBD creates a surface recognized by 
transcriptional coactivators (Moras and Gronemeyer, 1998). This activation function domain 
(AF-2) of the liganded LBD physically interacts with steroid receptor coactivator 1 (SRC1) and 
other members of the p160 family (He et al., 1999). The NTD contains AF-1 and AF-5 domains, 
which recruit transcriptional coactivators in a ligand-independent manner (Shen and Coetzee, 
2005). Additionally, the NTD contains WxxLF and FxxLF motifs that facilitate interaction 
between the NTD and AF-2 in liganded AR, which can promote or compete with cofactor 
binding (Figure 1.1) (He et al., 1999; He et al., 2000). 
 Ligand-bound AR can translocate to the nucleus, undergo additional post-translational 
modifications, dimerize and bind at androgen-responsive elements (AREs) in the genome 
(Feldman and Feldman, 2001). Once bound in the genome, AR recruits coregulators to induce or 
repress transcription of target genes. Coactivators include histone acetylases that function to 
open chromatin and facilitate transcription. On the other hand, corepressors such as nuclear 
receptor corepressor 1 (NCoR1) are histone deacetylases that close chromatin and inhibit 
transcription. Expression studies have shown that AR activates or represses a comparable 
number of targets (DePrimo et al., 2002; Jones et al., 2005). 
 The consensus ARE is an inverted repeat of sequence 5'-GG(A/T)ACAnnnTGTTCT-3' 
(Beato, 1989; Roche et al., 1992). However, similar to other transcription factors, only a minority 
of individual AR binding sites are a perfect match to the consensus. The inverted repeat is also 
the consensus sequence for other steroid hormone receptors including glucocorticoid, 
progesterone and mineralocorticoid receptors. AR can also bind more selectively to elements that 
resemble direct repeats but are actually single half-sites or non-consensus sites (Sahu et al., 2014; 
Tewari et al., 2012). 
5 
 
 AR often binds at distal enhancer regions in addition to proximal promoters. Some of the 
most well-characterized enhancers are up to several dozen kilobases (kb) upstream of the target 
gene's transcription start site (TSS), e.g. the KLK3 (-4 kb) and TMPRSS2 (-13 kb) enhancers. 
However, enhancers can be upstream or downstream of the associated gene, and can be hundreds 
of kb away. Chromatin immunoprecipitation-microarray (ChIP-chip) and more recent ChIP-
sequencing (ChIP-seq) studies reveal up to tens of thousands of AR binding sites in the genome 
(Chen et al., 2013; Sahu et al., 2014; Yu et al., 2010). Genes may be regulated by multiple AR 
binding sites. Additionally, many AR binding sites are in gene deserts and therefore their 
function is unknown. ChIP-seq studies have also identified the FOXA1 consensus sequence as 
the top motif aside from the ARE sequence at AR-bound sites in prostate cells. Further 
experiments demonstrate that FOXA1 acts as a "pioneer factor" for AR, binding to many 
genomic sites first and facilitating subsequent binding of liganded AR (Lupien and Brown, 
2009). 
 Through activation and repression of AR target genes, androgen signaling can produce 
physiological outcomes such as cell proliferation, differentiation, development or survival. These 
effects depend on tissue type and developmental stage. In the adult prostate, AR drives a gene 
expression program that is both pro-survival and pro-differentiation. During early tumorigenesis 
AR signaling is dysregulated, tipping the balance for later proliferation and invasion. In 
castration-resistant prostate cancer (CRPC), the AR transcriptional program diverges 
substantially from that in normal prostate (Sharma et al., 2012). A more thorough understanding 
of the factors influencing this "oncogenic switch" in AR behavior at both early and late disease 
stages is critical. 
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Androgen Receptor Variation in Prostate Cancer and Other Human Syndromes 
 The human AR gene is on the X chromosome and contains a CAG repeat in exon 1 that 
encodes a polyglutamine tract (Q-tract) in the N-terminal domain of the AR protein. Length of 
the CAG repeat (and thus Q-tract) is polymorphic in the population, with a median length of 21 
repeats and a normal range of 9 to 37 Qs (Zitzmann and Nieschlag, 2003). Association of Q-tract 
variation with several syndromes is well established. Extremely long tracts (38 or more repeats) 
cause spinobulbar muscular atrophy (SBMA), a neurodegenerative condition also known as 
Kennedy disease (La Spada et al., 1991). SBMA patients suffer from motor neuron and skeletal 
muscle degeneration beginning any time after puberty, but more frequently in adults in their 
fifties. Molecular pathogenesis of SBMA occurs in part through proteotoxic gain of function of 
the expanded polyglutamine AR over time, in a ligand-dependent manner (Chua and Lieberman, 
2013), hence the absence before puberty and the tendency for later onset. SBMA occurs only in 
men, and even women with homozygous mutations remain unaffected, highlighting the androgen 
dependence of the phenotype. The toxic gain of function mechanism has parallels with 
Huntington disease and other expanded polyglutamine-associated neurological syndromes 
(Zoghbi and Orr, 2000). 
 AR transcriptional activity is inversely proportional to the length of the Q-tract in model 
systems in vitro and in vivo (Albertelli et al., 2006; Simanainen et al., 2011; Wang et al., 2004). 
This occurs in part due to decreased AR-coactivator interaction with the expanded tract (Irvine et 
al., 2000) and greater intramolecular interaction between the N- and C-termini with fewer 
repeats, facilitating coactivator recruitment (Buchanan et al., 2004; Ding et al., 2004). Men with 
SBMA may display partial androgen insensitivity syndrome (PAIS) including infertility, 
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hypogonadism or impotence (Chua and Lieberman, 2013) due to decreased AR transcriptional 
function. 
 AR Q-tract length varies with ethnicity, with the shortest average length in African 
Americans. That population also has a higher incidence of PCa, which in combination with the in 
vitro findings led to the early hypothesis that a short Q-tract increases PCa risk through a lifetime 
of increased AR signaling (Coetzee and Ross, 1994). Furthermore, the Q-tract has been observed 
to somatically shorten during cancer progression, suggesting a role in oncogenesis (Alvarado et 
al., 2005). Despite an initial association in some studies, large studies showed that the Q-tract 
alone was not associated with PCa risk (Lindstrom et al., 2010; Price et al., 2010). However, a 
short Q-tract in combination with specific haplotypes in genes along the androgen synthesis 
pathway, including CYP17A1 and SRD5A2, is associated with an increased risk of PCa 
(Lindstrom et al., 2006a; Lindstrom et al., 2006b). A short Q-tract has also recently been 
associated with a higher frequency of PCa that is positive for the recurrent TMPRSS2-ERG gene 
fusion (Bastus et al., 2010; Yoo et al., 2014), which will be discussed below, suggesting that AR 
variation may play a role in certain subtypes of PCa. 
 Proper AR activity is critical to normal prostate differentiation and function. In men and 
mice, inherited mutations in AR that truncate the protein prior to the LBD, or that otherwise 
inactivate the protein, cause partial or complete androgen insensitivity syndrome (PAIS, CAIS) 
depending on the severity of the mutation. These males may display infertility, hypogonadism, or 
lack male secondary sex traits despite the presence of a normal Y chromosome. Intriguingly, in 
PCa an AR protein lacking the LBD due to either alternative splicing or a somatic truncating 
mutation may promote resistance to hormonal therapy due to constitutive activity (see below) 
(Dehm et al., 2008), highlighting the divergent functional capability of AR in different contexts. 
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Prostate Cancer 
 The prostate is a gland approximately the size of a large walnut, surrounding the urethra 
just below the urinary bladder. It is composed of 4 zones: the peripheral zone, which is the 
largest portion of the prostate and the site of the majority of PCa, the transition zone, where 
benign prostatic hyperplasia (BPH) originates, the central zone and the anterior fibromuscular 
stroma. The tissue is structured histologically as glands comprised of luminal and basal epithelial 
cells, surrounded by stromal smooth muscle cells. The first stage of cancer progression is the 
onset of prostatic intraepithelial neoplasia (PIN), a "precursor lesion" where epithelial cells 
become atypical with enlarged nucleoli and increased proliferation, but the neoplastic cells 
remain contained within the basement membrane (Brawer, 2005). Adenocarcinoma is defined as 
the invasion of epithelial cells into the surrounding stromal tissue, and metastasis is the spread of 
these cells to distal sites, often bone or lymph nodes (Figure 1.2) (Abate-Shen and Shen, 2002). 
 PCa is the most common non-cutaneous cancer and the second-deadliest cancer among 
men in the United States and other Western countries. This year it is estimated that over 220,000 
men will be diagnosed with PCa and more than 27,000 men will die in the United States as a 
result of the disease (Siegel et al., 2015). If detected early, localized PCa can generally be cured 
with radiation or radical prostatectomy. However, metastatic disease often becomes resistant to 
current therapies despite an initial favorable response, and these patients succumb to their 
treatment-refractory cancer. Thus, a deeper understanding of the molecular interactions 
underlying disease progression is necessary in order to improve upon existing treatments and to 
develop new ones. 
 Beyond developing novel therapeutics for PCa patients, a primary question is which 
patients require aggressive treatment. Age is the biggest risk factor for PCa, and the majority of 
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localized tumors are indolent, meaning that often the cancer will not substantially affect the 
patient's overall health within their lifetime. The majority of men over 70 show some degree of 
PIN or even localized PCa upon autopsy, regardless of a diagnosis within their lifetime. In other 
words, most PCa patients die with, not because of, their localized tumor (Waterbor and 
Bueschen, 1995). However, it is difficult to distinguish early PCa that will metastasize from that 
which will not. Improved biomarkers for aggressive vs. indolent disease could spare substantial 
healthcare resources by identifying those for whom watchful waiting would suffice. 
 
Prostate Cancer Detection, Post-Metastatic Therapy and Resistance 
 Because prostate tumors are dependent on androgen signaling, previous therapies have 
targeted circulating androgen production or the AR protein. Testicular testosterone is the primary 
circulating androgen, however the adrenal gland secretes a low amount of androgens and 
testosterone precursors as well (Labrie, 2011). Hence, the original hormone treatment for PCa 
developed by Drs. Huggins and Hodges in 1941 was orchiectomy, which involves surgical 
removal of the testes (castration) (Huggins and Hodges, 2002). In the present day, "medical 
castration" is often performed with drugs that reduce circulating testosterone to levels equivalent 
to surgical castration. In most patients, this "androgen ablation" monotherapy temporarily results 
in tumor regression and a drop in prostate-specific antigen (PSA) levels. 
 Previously primary PCa was detected by digital palpation, but a more sensitive marker 
proved to be serum levels of the PSA protein, encoded by the KLK3 gene and a direct target of 
AR. Rising PSA levels are a clinical indicator of resistance to androgen ablation therapy and 
resurgent AR activity. While useful for tracking disease progression in PCa patients, PSA 
screening for PCa risk in otherwise healthy men is very controversial and screening 
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recommendations vary (Etzioni et al., 2002; Etzioni and Thompson, 2014). Some studies have 
revealed a high rate of overdiagnosis, i.e. men with elevated PSA but no sign of PCa upon an 
invasive biopsy, such that there may be high cost but little overall survival benefit from 
screening the general population absent additional risk factors. 
 The feedback system of the hypo-pituitary-adrenal-gonadal axis maintains testosterone 
levels within a normal physiological range and offers opportunities for clinical intervention, i.e. 
targets for androgen ablation therapy. When the hypothalamus detects low testosterone levels, it 
produces luteinizing hormone-releasing hormone (LHRH), which signals to the pituitary to 
produce luteinizing hormone (LH), which signals to the testes to produce testosterone. Rising 
testosterone signals back to the hypothalamus to slow LHRH production (Kluth et al., 2014). 
LHRH agonists or antagonists are drugs commonly used to disrupt testosterone production in 
PCa patients. LHRH antagonists prevent the pituitary from responding to LHRH, causing 
reduced LH production and thus reduced testosterone production. LHRH agonists stimulate the 
system to temporarily increase testosterone production, yet this "burst" ultimately leads to 
reduced LHRH and reduced testosterone over time (Kluth et al., 2014). Reducing testosterone 
production in this manner is initially effective in causing regression of prostate tumors. 
 Antiandrogens are non-steroidal competitive inhibitors that bind the LBD of the AR 
protein and may be given in combination with androgen ablation, resulting in total androgen 
blockade. Hydroxyflutamide and bicalutamide are among the earlier antiandrogens, and more 
recently Enzalutamide (MDV3100) was developed as a more potent compound (Mukherji et al., 
2012). Antiandrogens act by binding to the AR LBD and competitively inhibiting agonist 
binding, while Enzalutamide blocks nuclear entry as well. The conformation of antiandrogen-
bound AR is altered such that it disrupts AF-2 and prevents interaction with the normal 
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complement of coregulators, and thus normal transcriptional activity is abrogated despite nuclear 
translocation and DNA binding. In addition, antagonists induce a partially distinct AR genomic 
binding profile (Chen et al., 2014). 
 Androgen synthesis enzymes have been targeted with small molecules as well. 
Abiraterone acetate is a rationally designed drug that directly inhibits the CYP17A1 enzyme that 
catalyzes the initial steps of testosterone production, and is given after failure of androgen 
ablation therapy (Bryce and Ryan, 2011). While this drug successfully reduces androgen 
synthesis in the adrenal gland and tumor, as well as the testes like Lupron, and extends life by 
several months in CRPC patients, resistance can also develop. Dutasteride and finasteride are 
inhibitors of the DHT conversion enzymes SRD5A1 and SRD5A2, and are used in treatment of 
BPH (Wu et al., 2014). To determine whether a long-term decrease in androgen signaling could 
reduce PCa risk, men in the Prostate Cancer Prevention Trial were given finasteride or placebo 
and followed for up to 18 years (Thompson et al., 2013). The finasteride group had a lower rate 
of PCa but a greater proportion with high-grade disease, and there was no significant difference 
in long-term survival. This finding highlights the heterogeneity of PCa and suggests that a given 
therapy may benefit or harm different subsets of patients. 
 As implied by the name CRPC, AR remains active despite ongoing therapy (Culig et al., 
1998). This can occur through several mechanisms, including treatment-selected mutations in 
AR (O'Mahony et al., 2008; Steinkamp et al., 2009). Somatic mutations in the AR LBD can 
result in a promiscuous receptor able to be activated rather than repressed by antiandrogens, e.g. 
the T877A mutation that is activated by hydroxyflutamide as well as adrenal androgens (Tan et 
al., 1997). Similarly, AR-V716M can be activated by adrenal androgens and progesterone (Culig 
et al., 1993), and in a patient treated with hydroxyflutamide this mutation was the dominant AR 
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expressed in multiple metastases (Steinkamp et al., 2009). Furthermore, truncating mutations can 
introduce a stop codon prior to the LBD (Ceraline et al., 2004), or tumor cells can express 
alternatively spliced isoforms of AR that incorporate novel exons after the DBD and truncate 
prior to the LBD (Dehm and Tindall, 2011; Dehm et al., 2008). These AR variants cannot bind 
hormone, and are constitutively nuclear and transcriptionally active despite androgen ablation or 
antiandrogen therapy. In a small study, expression of truncated splice variant ARs is associated 
with Enzalutamide and abiraterone acetate resistance and decreased survival (Antonarakis et al., 
2014). Missense mutations in AR can also facilitate abnormal transactivation of targets. The N-
terminal transactivation domain mutants E231G (seen in mice) and E255K (the corresponding 
residue in humans) promote increased stability and nuclear localization of AR (Han et al., 2005; 
Steinkamp et al., 2009), due in part to decreased interaction with the ubiquitin ligase C-terminal 
HSP-interacting protein (CHIP) (Han et al., 2005). The W435L mutation in the WxxLF motif 
promotes increased transactivation via enhanced N-C interaction (Steinkamp et al., 2009). 
 Genes encoding androgen synthesis enzymes can be aberrantly activated in PCa, resulting 
in intra-tumor androgen synthesis which circumvents the normal feedback loop. AR can also 
become overexpressed in tumor cells due to gene locus amplification or other dysregulation, 
allowing a hypersensitive response to minute levels of circulating androgens or even to 
antiandrogens. Overexpression of AR coactivators can also sensitize the androgen response 
(Feldman and Feldman, 2001; Heinlein and Chang, 2004; Shen and Abate-Shen, 2010). AR can 
also be activated in a ligand-independent manner through phosphorylation by epidermal growth 
factor (EGF) or insulin-like growth factor (IGF) signaling (Culig et al., 1994). Finally, the 
requirement for AR signaling can be bypassed via upregulation of alternative signaling pathways 
in the tumor cell such as BCL2 (Feldman and Feldman, 2001; Furuya et al., 1996). 
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Mouse Models of Prostate Cancer 
 The mouse has proven to be a valuable experimental system in which to study AR and 
PCa (Abate-Shen and Shen, 2002; Robins, 2011), particularly at early disease stages for which 
human samples are unavailable. Furthermore, mice allow genetic manipulation within a 
homogeneous background. However, autochthonous mouse models of PCa rarely metastasize to 
bone, the most frequent metastatic site in humans. Additionally, the initiating genetic lesion is 
uniformly present, in contrast to human disease which likely originates in one or a subset of 
cells.  
 While the physiological role of the mouse prostate is similar to humans, the structure is 
distinct. Unlike the zonal human prostate, the mouse prostate is comprised of 4 pairs of lobes: the 
anterior prostate (AP), ventral prostate (VP) and the dorsal prostate (DP) and lateral prostate 
(LP), which are often dissected and analyzed together as the dorsolateral prostate (DLP) (Cunha 
et al., 1987). While mice do not naturally develop PCa in their lifetime, in contrast to the high 
frequency in humans, a number of genetically engineered mouse models (GEMMs) of PCa have 
been established. An early model of aggressive, metastatic PCa was the transgenic 
adenocarcinoma of the mouse prostate (TRAMP) mouse (Greenberg et al., 1995). TRAMP mice 
harbor a transgene expressing the SV-40 T antigen under control of the rat probasin promoter, 
which drives prostate-specific androgen-induced expression. The disease course in TRAMP 
parallels that in humans, with lesions initiating as PIN before progressing to invasive 
adenocarcinoma and metastasis, and with CRPC developing in castrated mice (Gingrich et al., 
1996). However, TRAMP tumors show frequent neuroendocrine differentiation (Kaplan-Lefko 
et al., 2003), which is less common in humans. Importantly, this mouse model helped to establish 
that PIN is a precursor to adenocarcinoma. 
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 More accurate mouse models of PCa reflect mutations seen in patients, including loss of 
Nkx3-1, a tumor suppressor and prostate differentiation gene (Bowen et al., 2000). Nkx3-1
-/-
 and 
even Nkx3-1
+/-
 mice develop PIN but do not progress to adenocarcinoma (Kim et al., 2002a). 
Mice expressing a prostate-targeted c-Myc transgene, modeling the oncogenic MYC 
overexpression seen in human PCa, develop PIN with progression to adenocarcinoma, 
suggesting a driver role (Ellwood-Yen et al., 2003). Notably, tumors in the c-Myc mice show 
reduced Nkx3-1 expression. 
 Mice with one allele of the tumor suppressor Pten knocked out in the germline (Pten
+/-
) 
develop PIN but do not progress to adenocarcinoma. The mice are predisposed to additional 
cancers as well, including lymphoma (Alimonti et al., 2010; Trotman et al., 2003). However, 
Nkx3-1
+/-
;Pten
+/-
 mice progress to adenocarcinoma, while mice with either single lesion do not 
(Kim et al., 2002b). This suggests that reduced expression of multiple tumor suppressors can 
accelerate cancer progression, and supports the notion that multiple alterations are required for 
tumorigenesis. 
 In addition to the autochthonous mouse models described above, immunodeficient mice 
may be implanted with malignant cells as xenografts. The cells may first be transduced with viral 
constructs to stably overexpress or knock down a given gene, or may be otherwise manipulated 
(Bertram et al., 2006; Chen et al., 2004; Thomas et al., 2013). Compared to GEMMs, these 
models can use human cells and facilitate rapid experiments to test the effects of drug treatment 
or gene over- or underexpression on tumor growth and metastasis. However, such experiments 
may not consider the influence of the microenvironment. 
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Androgen Receptor Variation in Mouse Models of PCa 
 In work led by Megan Albertelli, the Robins lab previously asked how naturally 
occurring variation in AR, reflecting a stronger or weaker androgen axis, could influence PCa 
initiation and progression, using the mouse for its homogeneous genetic background (Albertelli 
et al., 2008; Albertelli et al., 2006). The mouse AR protein is approximately 15% divergent from 
the human AR in the N-terminal domain, including an interrupted Q-tract, but otherwise the 
protein sequences are nearly identical. Exon 1 of the human AR gene, which encodes the entire 
N-terminal domain including the Q-tract, was knocked into the mouse Ar locus to produce a 
"humanized AR" mouse, with alleles encoding short (hAR
12Q
), medium (hAR
21Q
) or long 
(hAR
48Q
) Q-tracts. The Q-tract variants alone did not affect survival or fertility, and the mice did 
not develop PCa. However, several androgen-induced genes in the prostate showed a trend 
toward increased expression with the "stronger" hAR
12Q
 allele or reduced expression with the 
"weaker" hAR
48Q
 allele, reflecting differences at the molecular level due to AR transcriptional 
activity (Albertelli et al., 2006). The varying strength of the androgen axis was also evident as 
increased seminal vesicle weight or overall prostate weight with the stronger allele (Albertelli et 
al., 2006; Simanainen et al., 2011). While a 48Q AR would cause SBMA in man, mice require at 
least an 112Q AR to develop a similar neurodegenerative phenotype (Chevalier-Larsen et al., 
2004). 
 When the humanized AR mice were crossed onto the TRAMP background, effects on 
cancer initiation, progression and treatment response were observed (Albertelli et al., 2008; 
Robins et al., 2008). Histological analysis revealed a higher percentage of the prostate epithelium 
composed of PIN at 12 weeks in hAR
12Q
 mice. Palpable tumors were detected later in the hAR
48Q
 
than hAR
12Q
 mice. Interestingly, the hAR
12Q
 mice had increased survival from the time of tumor 
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detection and had more well-differentiated tumors. This finding may reflect opposing functions 
of AR in promoting growth and proliferation as well as differentiation. Furthermore, the Q-tract 
affected response to castration therapy. Tumors in the hAR
48Q
 TRAMP mice did not respond to 
castration, and these mice died earlier. In contrast, half of the castrated hAR
12Q
 mice showed a 
survival benefit, but half never developed a palpable primary prostate tumor and died of 
aggressive metastatic disease (Albertelli et al., 2008; Robins et al., 2008). As before, these results 
show the divergent function of AR. In hAR
48Q
 mice, the weaker AR permits progression by AR-
independent growth pathways. The divergent response of castrated hAR
12Q
 mice highlights the 
heterogeneity and stochastic nature of PCa. This echoes the findings of the Prostate Cancer 
Prevention Trial, where finasteride treatment successfully lowered the overall rate of PCa but 
resulted in more aggressive tumors (Thompson et al., 2013). 
 In additional transgenic mouse models, wildtype and mutant AR have been 
overexpressed. One group reported that transgenic overexpression of the AR-E231G mutant 
resulted in metastatic PCa and altered prostate gene expression while AR-WT did not (Han et al., 
2005; Thompson et al., 2011). Transgenic expression of a truncated AR splice variant that is 
constitutively active in vitro caused PIN with upregulation of epithelial to mesenchymal 
transition (EMT) genes (Sun et al., 2014). These results suggest that AR dysregulation may 
promote oncogenesis, while an increase in wildtype AR activity via a short Q-tract (Albertelli et 
al., 2006) or overexpression (Thompson et al., 2011; Zong et al., 2009) does not. However in a 
xenograft study using AR-positive PCa cell lines, an increase in AR expression was sufficient to 
drive progression to CRPC (Chen et al., 2004). Moreover, AR can cooperate with additional 
mutations to alter disease progression (Albertelli et al., 2008; Zong et al., 2009). 
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  These findings highlight the duality of AR; it normally promotes cell 
differentiation and tissue maintenance, but can also enhance cell proliferation and tumorigenesis 
(Gao et al., 2001). In TRAMP mice, the stronger AR drove earlier tumor growth yet also 
maintained better differentiation of those tumor cells, and resulted in differential response to 
therapy. Therefore, an "oncogenic switch" seems to occur early in prostate tumorigenesis in 
which AR is redirected from its normal pro-differentiation gene expression program to favor 
expression of genes promoting proliferation and invasion. Understanding the factors that 
contribute to this oncogenic switch requires determining the impact on AR signaling from 
additional somatic mutations that are commonly observed in tumors from human PCa patients. 
 
Recurrent Gene Fusions in Prostate Cancer 
 Scott Tomlins and Arul Chinnaiyan at the University of Michigan opened up a new field 
in PCa research when they discovered recurrent gene fusions involving E26 transformation-
specific (ETS) transcription factor genes fused to androgen-responsive promoters. The structure 
of these fusions immediately suggested how AR may drive oncogene activation to initiate PCa. 
The ETS genes ERG and ETV1 were first identified as highly expressed outliers in a 
bioinformatic analysis of several patient data sets (Tomlins et al., 2005). After ruling out 
amplification of the ERG and ETV1 genomic loci and showing reduced expression of the 5' 
exons relative to the rest of the gene, Tomlins et al. used 5' RNA ligase-mediated rapid 
amplification of cDNA ends (RLM-RACE) to identify potential upstream gene fusion partners. 
The 5' noncoding exons and upstream regulatory region of the TMPRSS2 gene were found to be 
fused to the 3' coding exons of ERG or ETV1 via genomic translocation (Tomlins et al., 2005). 
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TMPRSS2 is an androgen-induced gene, which explained the upregulation of ERG and ETV1, 
neither of which are highly expressed in normal prostate. 
 ETS transcription factors are cell cycle regulators capable of controlling growth, 
development and proliferation, and ETV1 is important for muscle and nervous system 
development. In vitro, overexpression of exogenous ERG or ETV1 in benign prostate cell lines 
results in increased invasion, while knockdown in fusion-positive PCa cell lines decreases 
invasion (Mesquita et al., 2014; Tomlins et al., 2007; Tomlins et al., 2008a). ERG and ETV1 
overexpression mimic RAS/MAPK signaling in benign prostate cells (Hollenhorst et al., 2011a). 
A recent study attaining ERG knockdown with an inducible short hairpin RNA (shRNA) 
demonstrated that ERG drives proliferation and inhibits luminal and neuronal differentiation 
(Mounir et al., 2014). Furthermore, the matrix metalloproteinase genes MMP7 and MMP9 are 
transcriptional targets of ERG and ETV1 (Shin et al., 2012; Tian et al., 2013), which suggests 
that promoting a breakdown of the extracellular matrix is one way that overexpressed ETS 
factors increase invasiveness. 
 Recurrent gene fusions such as BCR-ABL have been previously identified in leukemia, 
and the BCR-ABL protein has proven to be a valuable therapeutic target (Jabbour and 
Kantarjian, 2014). ETS genes were known to be involved in gene fusions in Ewing's sarcoma, 
most frequently FLI1 but also ERG and ETV1 (Jeon et al., 1995; May et al., 1993; Sorensen et 
al., 1994). ETV1 is also a key transcription factor in gastrointestinal stromal tumors (GIST) (Ran 
et al., 2015). The identification of ETS fusions in PCa suggested that it may be possible to 
stratify patients by molecular alteration and design new targeted therapies. 
 ERG is fused to TMPRSS2 in approximately 50% of prostate tumors, and occasionally to 
alternative upstream partners (Han et al., 2008). ETV1 is fused to TMPRSS2 in some cases, but 
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more often to a broader spectrum of upstream partners, collectively in 5-10% of tumors. The 
ETS genes ELK4, ETV4 and ETV5 are each similarly rearranged in 2-5% of tumors (Rubin et al., 
2011). A distinct class of prostate tumors overexpress SPINK1, though not mediated by a gene 
fusion event, in approximately 10% of patients (Tomlins et al., 2008b). Importantly, the vast 
majority of upstream ETS fusion partners are androgen-induced genes, though housekeeping 
genes or human endogenous retroviruses (HERVs) drive high expression in a subset of ETS 
fusions (Rubin et al., 2011). 
 Not only is expression of the ETS fusions generally androgen-induced, but androgen 
stimulation of benign prostate cells can promote formation of the TMPRSS2-ERG fusion (Bastus 
et al., 2010; Lin et al., 2009; Mani et al., 2009). The TMPRSS2 and ERG genes lie 2.8 Mb apart 
on chromosome 21. Concomitant recruitment of AR and topoisomerase II beta (TOP2B) induces 
double-strand breaks, and inappropriate repair results in excision of the intervening sequence and 
formation of the fusion product (Haffner et al., 2011). Despite the high frequency of ETS gene 
rearrangements in prostate tumors, it remains questionable whether the presence of a fusion 
alone indicates poor prognosis. A large study showed no association between the TMPRSS2-
ERG fusion and biochemical recurrence after prostatectomy (Pettersson et al., 2012; Rubin et al., 
2011; Taris et al., 2014a). However, TMPRSS2-ERG has diagnostic utility, and is useful in 
distinguishing high-grade PIN (HG-PIN) and PCa from other histological abnormalities (Barbieri 
and Tomlins, 2014). 
 In mice transgenic overexpression of ERG or ETV1 in the prostate is insufficient for PCa 
but results in PIN at variable penetrance, reflecting heterogeneous disease even in a 
homogeneous genetic background (Carver et al., 2009; King et al., 2009; Klezovitch et al., 2008; 
Shin et al., 2009; Tomlins et al., 2007; Tomlins et al., 2008a). Similarly when mouse prostate 
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cells overexpressing ERG are transplanted into the prostate of immunocompromised mice, ERG 
overexpression induces PIN (Zong et al., 2009). These in vitro and in vivo results suggest that 
ETS factors play a role in early neoplasia. However, similar to overexpression of AR alone, an 
increase in activity may not be sufficient to drive complete transformation. Additional 
dysregulation or cooperating genomic insults such as tumor suppressor loss may be required to 
promote progression to overt PCa, at least in mouse models. 
 
PTEN Loss in Prostate Cancer 
 Expression of the phosphatase and tensin homolog gene (PTEN) is reduced or lost due to 
genomic deletion or inactivating mutations in more than half of prostate tumors, and it is 
frequently lost in other cancers as well (Taylor et al., 2010). PTEN is a tumor suppressor gene 
whose protein product is a phosphatase that targets the signaling molecule phosphatidylinositol-
3,4,5-trisphosphate (PIP3). In turn, PIP3 reduction inhibits activation of the phosphoinositide 3-
kinase (PI3K) / protein kinase B (AKT) signaling pathway (Stiles et al., 2004). PI3K 
phosphorylates AKT at Serine-473, and phospho-AKT (pAKT) activates mammalian target of 
rapamycin (mTOR) signaling as well as other pro-survival, pro-proliferation pathways. PTEN 
loss is associated with worse clinical prognosis in PCa patients (Bismar et al., 2011) and 
progression to CRPC, as shown in xenograft experiments where PTEN-deficient tumors 
continued to grow despite castration (Bertram et al., 2006). 
 Complete germline deletion of Pten in mice is lethal, but hypomorphic alleles reveal that 
even 30% Pten expression (Pten
hy/-
) is viable. Furthermore, penetrance of multiple cancers 
including PCa is inversely correlated with Pten expression level, with PIN developing in Pten
+/-
 
mice and progression to prostate adenocarcinoma occurring in Pten
hy/-
 mice (Alimonti et al., 
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2010; Trotman et al., 2003). Conditional Pten knockout in the mouse prostate, achieved with 
floxed Pten (Pten
flox/flox
) and a probasin-driven Cre recombinase transgene, avoids the lethality 
caused by germline deletion and results in high-penetrance adenocarcinoma (Ma et al., 2005; 
Wang et al., 2003). 
 The AR and PI3K/AKT pathways reciprocally inhibit one another, meaning that 
treatments targeting one pathway can lead to enhanced activity of the other (Carver et al., 2011; 
Mulholland et al., 2011). AR inhibits pAKT indirectly via the androgen-induced gene FKBP5, 
whose protein product upregulates PHLPP, the phosphatase for pAKT. Likewise, PTEN loss 
inhibits AR transcriptional activity indirectly via activation of the polycomb repressive complex 
member EZH2, as well as c-JUN and EGR1 (Mulholland et al., 2011). Combination therapy, i.e. 
inhibiting AR and PI3K/AKT signaling simultaneously, more potently represses the growth of 
PCa cells in vitro and in xenograft models and may have therapeutic utility in patients (Carver et 
al., 2011; Mulholland et al., 2011; Thomas et al., 2013). 
 
Cooperation Between ETS Fusions and PTEN Loss 
 In patient tumors, genomic loss of one or both copies of PTEN is significantly correlated 
with the presence of the TMPRSS2-ERG fusion (Bismar et al., 2011; King et al., 2009; Krohn et 
al., 2012), leading to the hypothesis that the two lesions cooperate in oncogenesis. Prostatic ERG 
overexpression in Pten
+/-
 mice results in progression to adenocarcinoma (Carver et al., 2009) or 
at least higher penetrance PIN (Baena et al., 2013; King et al., 2009) than in Pten
+/-
 mice alone, 
supporting cooperation. In a report published while this thesis project was ongoing, prostatic 
ETV1 overexpression in Pten
+/-
 mice resulted in higher-penetrance PIN compared to Pten 
reduction alone, but still without progression to adenocarcinoma (Baena et al., 2013). In 
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Pten
flox/flox
 mice, concurrent ERG overexpression resulted in greater progression to 
adenocarcinoma (Chen et al., 2013) or no additive effect (Baena et al., 2013). The combination 
of ETV1 overexpression and prostatic Pten deletion resulted in earlier death than in Pten
flox/flox
 
mice alone (Baena et al., 2013). In experiments where mouse prostate cells were transduced with 
lentiviral constructs and re-implanted into immunocompromised mice, stable overexpression of 
ERG alone in the implanted cells resulted in PIN, but simultaneous AKT overexpression or 
PTEN knockdown resulted in progression to adenocarcinoma (Zong et al., 2009). While it 
appears that ETV1 and ERG have the potential to cooperate with Pten loss or reduction in 
prostate oncogenesis, results vary between studies. This may reflect differences in mouse strain 
background, time points and the nature of the transgene or knocked-in construct, as well as 
human-mouse differences. 
 Intriguingly, in the mouse prostate tissue re-implantation experiments, lentiviral AR 
overexpression alone did not induce any neoplasia, but stable AR plus ERG overexpression 
resulted in adenocarcinoma (Zong et al., 2009). This particular finding suggests that increased 
activity level of wildtype AR can influence PCa progression in the context of oncogene 
activation, which is in line with the results in hAR;TRAMP mice (Albertelli et al., 2008). 
Together, those discoveries beg the question of how variation in AR or the androgen axis 
(modeled by polymorphic Q-tract length) affects PCa progression driven by ETS overexpression 
and PTEN reduction. 
 
Cell Culture Models of Prostate Cancer 
 Cell lines derived from human PCa metastases as well as normal prostate tissue have also 
been important for molecular studies of AR and other important signaling pathways, facilitating 
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biochemical analyses not possible in vivo. Numerous PCa cell lines are commercially available 
and commonly used (Sobel and Sadar, 2005a, b). Some cell lines were cultured directly from 
tumors, while others were immortalized from normal prostate tissue or passaged through mouse 
xenografts. Each line has distinct properties such as mutated, overexpressed or absent AR, loss 
or overexpression of AR cofactors, ETS fusions, or other features that suit different cell lines to 
specific experimental questions. A disadvantage of cell lines is that they generally represent late 
stage disease from a single tumor. Therefore, biological replicates in most cell culture 
experiments represent responses to culture conditions rather than individual variation. Cell lines 
can also acquire mutations in culture, and experiments with the same cell line in different labs 
may not give uniform results. Finally, a monolayer of cells does not recapitulate the complex 
milieu of cell types and signaling factors present in tissue. Nevertheless, PCa cells are a valuable 
tool in AR and PCa biology. 
 LNCaP cells, derived from a lymph node PCa metastasis, are used frequently to study AR 
and PCa (Horoszewicz et al., 1983). LNCaP cells express AR and respond to androgen 
stimulation, and a number of androgen-regulated gene sets have been characterized in LNCaP 
(DePrimo et al., 2002; Jones et al., 2005). Withdrawing androgen slows cell growth, but long-
term androgen ablation selects for androgen-independent cells, such as the LNCaP-abl line. 
Interestingly, LNCaP cells exhibit a biphasic androgen response where superphysiological levels 
inhibit growth, again highlighting the dual capacity of AR to promote proliferation or 
differentiation. The LNCaP AR harbors the T877A mutation in the LBD that allows activation 
by the antiandrogen hydroxyflutamide. This mutation likely arose in the patient in response to 
antiandrogen treatment, which selects for LBD mutations as a means of evading therapy 
24 
 
(O'Mahony et al., 2008; Steinkamp et al., 2009). The T877A mutation is found in post-treatment 
PCa patients and additional PCa cell lines as well. 
 LNCaP cells have lost PTEN expression, and overexpress ETV1 due to a genomic 
rearrangement placing the entire ETV1 locus in an androgen-responsive region (Tomlins et al., 
2007). Previous studies in LNCaP have reported that ETV1 enhances AR genomic binding and 
target gene induction (Baena et al., 2013; Chen et al., 2013; Shin et al., 2009). Predicted ETS and 
AR binding sites overlap throughout the genome, and indeed ETV1 and AR binding overlap in 
ChIP-seq experiments (Chen et al., 2013). The ETV1 and AR proteins can physically interact in 
a DNA-independent manner as well (Shin et al., 2009). 
 VCaP cells, derived from a vertebral metastasis, express wild-type but amplified AR, 
exemplifying another means to evade hormone therapy: androgen hypersensitivity through AR 
overexpression. VCaP cells retain PTEN expression and harbor a canonical TMPRSS2-ERG 
fusion gene. AR transactivation is strongly induced by androgen treatment, and ERG knockdown 
enhances AR activity, suggesting that ERG is repressing AR in this context (Baena et al., 2013; 
Mounir et al., 2014; Tomlins et al., 2008a; Yu et al., 2010). ChIP-seq experiments revealed that 
not only do ERG and AR binding sites significantly overlap, but ERG recruits the polycomb 
repressive complex (PRC), which places repressive histone 3 lysine 27 trimethylation 
(H3K27me3) marks near AR target genes (Yu et al., 2010). Exogenous ERG expression 
represses AR activity in additional PCa cell lines as well (Tomlins et al., 2008a; Yu et al., 2010). 
 Several other PCa cell lines such as PC3 and DU-145 have lost AR expression, but can 
exhibit androgen responsiveness when exogenous AR is introduced. Of note, some AR-negative 
PCa cell lines are more proliferative, invasive and tumorigenic than AR-positive cells. 
Expressing AR in PC3 cells and stimulating with DHT indeed slows proliferation (Mirochnik et 
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al., 2012), again highlighting the dual nature of AR: in some contexts it promotes proliferation 
and tumorigenesis, yet even in tumors and metastatic PCa cells it can promote differentiation. 
 Based on the in vitro studies described above, it has been suggested that while ERG and 
ETV1 both promote cell invasion, they have mainly divergent interactions with AR at the 
molecular level; ETV1 enhances AR activity while ERG represses it (Baena et al., 2013). 
However, in a mouse model ERG appears to promote activation of AR target genes, but only in 
prostate tumors of Pten
flox/flox
 mice (Chen et al., 2013). This suggests that interactions may differ 
in vivo vs. in vitro, and may depend on disease stage or the status of additional signaling 
pathways. Furthermore, the relationship between ETV1 and AR in contexts outside of LNCaP 
cells remains largely unexplored. 
 
AR Variation and ETS-Induced or PTEN Loss-Induced Neoplasia 
 In my thesis work I have explored how changes in the strength of the androgen axis, 
exemplified by Q-tract variation modeling the extremes in the human population, affect 
pathology resulting from oncogene activation and tumor suppressor loss in PCa. Mice expressing 
a short, median or long Q-tract AR were crossed with mice carrying a prostate-targeted ETV1 
transgene, or harboring germline loss of one Pten allele. These mice reflect human genetic 
variation in AR combined with common somatic mutations occurring in prostate tumors, and 
were examined with or without androgen ablation. Thus, this strategy encompasses the 
heterogeneity in human PCa, particularly in early-stage disease and the transition to malignancy, 
in the context of a varying androgen axis. 
 Global gene expression profiling by RNA-seq was performed to identify the downstream 
molecular consequences of interaction between the key transcription factors AR and ETV1 at 
26 
 
early and later stages of PCa progression. Particular attention was paid to genes and pathways 
dysregulated by ETV1 that are potentially targetable in therapy or that may have prognostic 
value. The effects observed in mice were directly tested in vitro with benign and malignant 
prostate cell lines modeling early, intermediate and late disease stages. Knockdown or 
overexpression of AR and ETV1 were performed to study direct interactions, with upstream 
genomic binding and downstream gene expression output analyzed. 
 Chapter 2 presents the mouse studies, which were recently published in the journal 
Hormones and Cancer (Higgins et al., 2015). Chapter 3 describes in vitro experiments that 
directly examine whether ETV1 alters AR target gene expression in different cellular contexts. 
Chapter 4 discusses the collective results and explores future scientific questions. 
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Figure 1.1: Functional Domains of Androgen Receptor 
 
 The 110 kDa AR protein contains distinct functional domains. The N-terminal 
transactivation domain (NTD) contains the ligand-independent activation functions AF-1 and 
AF-5. The DNA binding domain (DBD) consists of two zinc fingers. A hinge domain lies 
between the DBD and the ligand binding domain (LBD). Ligand binding induces a 
conformational change in the LBD, forming AF-2 which recruits transcriptional cofactors. The 
FQNLF and WHTLF motifs facilitate N-terminal C-terminal interaction and further facilitate 
cofactor binding. Adapted from (Robins, 2011).  
Q 
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Figure 1.2: Model of Prostate Cancer Progression 
 
 The normal prostate gland consists of luminal and basal epithelial cells surrounded by 
stromal smooth muscle. PIN, a PCa precursor lesion, occurs with atypia and uncontrolled 
proliferation of epithelial cells that remain contained within the basement membrane. Invasion 
through the basement membrane and into the stromal tissue constitutes adenocarcinoma (PCa). 
The invasive cells can eventually metastasize to distant sites. Adapted from (Abate-Shen and 
Shen, 2002). 
 
 AR is expressed throughout PCa progression, including in CRPC. ETS fusions generally 
occur as a relatively early event and are clonal within a given tumor focus. PTEN loss can occur 
as an early or late event, but is more frequent in advanced PCa. PTEN loss is associated with 
progression to CRPC. 
 
  
AR 
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PTEN Loss 
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Chapter 2 
 
Interaction of the androgen receptor, ETV1 and PTEN pathways in mouse prostate varies 
with pathological stage and predicts cancer progression 
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Abstract 
 
 To examine the impact of common somatic mutations in prostate cancer (PCa) on 
androgen receptor (AR) signaling, mouse models were designed to perturb sequentially the AR, 
ETV1 and PTEN pathways. Mice with "humanized" AR (hAR) alleles that modified AR 
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transcriptional strength by varying polyglutamine tract (Q-tract) length were crossed with mice 
expressing a prostate-specific, AR-responsive ETV1 transgene (ETV1
Tg
). While hAR allele did 
not grossly affect ETV1-induced neoplasia, ETV1 strongly antagonized global AR regulation 
and repressed critical androgen-induced differentiation and tumor suppressor genes, such as 
Nkx3-1 and Hoxb13. When Pten was varied to determine its impact on disease progression, mice 
lacking one Pten allele (Pten
+/-
) developed more frequent prostatic intraepithelial neoplasia 
(PIN).  Yet only those with the ETV1 transgene progressed to invasive adenocarcinoma. 
Furthermore, progression was more frequent with the short Q-tract (stronger) AR, suggesting 
that the AR, ETV1 and PTEN pathways cooperate in aggressive disease. On the Pten
+/-
 
background, ETV1 had markedly less effect on AR target genes. However, a strong 
inflammatory expression signature, notably upregulation of Cxcl16, was induced by ETV1. 
Comparison of mouse and human patient data stratified by presence of ETS fusion genes 
highlighted additional factors, some not previously associated with prostate cancer but for which 
targeted therapies are in development for other diseases. In sum, concerted use of these mouse 
models illuminates the complex interplay of AR, ETV1 and PTEN pathways in pre-cancerous 
neoplasia and early tumorigenesis, disease stages difficult to analyze in man. 
 
Introduction 
 
 Signaling through the androgen receptor (AR), a hormone-activated transcription factor 
in the nuclear receptor superfamily, is critical for normal prostate development and prostate 
cancer (PCa) progression (Abate-Shen and Shen, 2000). Androgen ablation therapy initially 
abrogates AR signaling and induces tumor regression, but tumors invariably recur despite 
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ongoing therapy and with continued AR expression and signaling (Shen and Abate-Shen, 2010). 
Even with recently developed therapies, disease progressing despite castrate levels of serum 
testosterone (termed castration-resistant prostate cancer [CRPC]) remains incurable (Knudsen 
and Kelly, 2011). A more thorough understanding of the interaction between AR and additional 
oncogenic pathways commonly dysregulated in PCa will be critical in identifying novel targets 
for therapeutic intervention. 
 Well known genetic variation in the AR protein occurs in the length of a polyglutamine 
tract (Q-tract) in the N-terminal domain. As shown by us and others, Q-tract length is inversely 
proportional to AR transcriptional strength in vitro and in vivo, as seen molecularly in 
differential target gene expression and physiologically in seminal vesicle weight (Albertelli et al., 
2006; Chamberlain et al., 1994; Simanainen et al., 2011). Q-tract length alone has not proven to 
be associated with PCa risk in humans but in combination with alleles of the androgen synthesis 
genes CYP17 and SRD5A2 the stronger AR increases PCa risk, supporting the notion that the 
androgen axis overall influences disease (Lindstrom et al., 2006a; Lindstrom et al., 2006b). We 
have previously shown that altering AR strength via Q-tract length variation on a homogenous 
genetic background modifies PCa onset and progression in an aggressive transgenic mouse 
model (Albertelli et al., 2008). Interestingly, AR genetic variation has recently been reported to 
be associated with the frequency of recurrent gene fusions in PCa (see below) (Bastus et al., 
2010; Yoo et al., 2014). This led us to examine the in vivo effect of AR variation on PCa driven 
by alterations commonly seen in human tumors. 
 Recurrent genomic rearrangements that fuse 5' regulatory elements of androgen-
responsive genes to the coding region of E26 transformation-specific (ETS) transcription factor 
genes occur in approximately half of human prostate tumors (Tomlins et al., 2007; Tomlins et 
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al., 2005). These fusions drive robust androgen-induced prostatic expression of ETS factors 
otherwise not expressed in the prostate. Fusions involving the ERG and ETV1 genes occur in 
approximately 50% and 5-10% of PCa, respectively (Tomlins et al., 2007; Tomlins et al., 2008a; 
Tomlins et al., 2005). ERG fusion events themselves are AR-mediated (Bastus et al., 2010), and 
prostate tumors are more likely to be ERG
+
 in patients harboring a short Q-tract (strong) AR 
allele (Bastus et al., 2010; Yoo et al., 2014), further suggesting cooperation between ETS and 
AR pathways. These fusions occur early in PCa ontogeny, and individual cancer foci or 
metastases are generally clonal for a given rearrangement, suggesting selection (Mehra et al., 
2007; Svensson et al., 2011). Prostatic overexpression of ETS factors induces PIN in some 
mouse models (Baena et al., 2013; Carver et al., 2009; King et al., 2009; Shin et al., 2009; 
Tomlins et al., 2007), and ETS factors promote invasion and alter gene expression in vitro 
(Baena et al., 2013; Hollenhorst et al., 2011a; Tomlins et al., 2007; Yu et al., 2010). However, it 
is unknown how modulation of the androgen axis, such as by AR genetic variation, alters the 
effect of ETS overexpression on tumorigenesis. 
 Perturbation of AR and ETS pathways alone does not lead to PCa in mice but additional 
genetic events cooperate in tumorigenesis. The tumor suppressor PTEN is frequently deleted or 
inactivated in a variety of human cancers, including PCa (Taylor et al., 2010). PTEN is a 
phosphatase that inactivates the PI3K target PIP3, in turn preventing phosphorylation of AKT 
and activation of downstream proliferation and survival pathways (Stiles et al., 2004). 
Furthermore, the AKT and AR signaling pathways can repress one another in a reciprocal 
manner (Carver et al., 2011; Mulholland et al., 2011). In PCa, PTEN loss is associated with poor 
prognosis and progression to CRPC (Bertram et al., 2006; Bismar et al., 2011). In mice Pten 
reduction causes PIN in a dose-dependent manner, while prostate-targeted Pten homozygous 
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deletion leads to adenocarcinoma (Alimonti et al., 2010; Carver et al., 2009; Lesche et al., 2002; 
Trotman et al., 2003). Several additional genetic hits can cooperate with Pten reduction to 
promote PCa, such as further tumor suppressor loss (as of Nkx3-1) (Abate-Shen et al., 2003) or 
oncogene activation (as of ERG) (Carver et al., 2009; King et al., 2009). ETV1 overexpression 
cooperates with prostate-specific Pten deletion to drive aggressive adenocarcinoma (Baena et al., 
2013). However, the interaction of ETV1 overexpression and Pten reduction, which is more 
common in patients than homozygous loss (Whang et al., 1998), is not fully understood, with 
recently reported results (Baena et al., 2013) differing from the findings described here. Further, 
the extent to which altered AR signaling influences disease progression in these contexts has not 
been addressed. 
 In the current study we used gene expression profiling to determine how varying the 
strength of the androgen axis would alter prostate pathology initiated by ETV1 overexpression 
and/or PTEN reduction in mice. A marked antagonism of the normal AR-regulated transcriptome 
in ETV1-transgenic prostates was largely abrogated on a Pten-hemizygous background. With 
reduced PTEN, ETV1 overexpression induced disease progression, as well as a pro-
inflammatory gene signature, both of which were impacted by AR strength. Integration of mouse 
and patient data revealed potential ETV1 regulation of known and novel PCa-associated genes, 
highlighting novel targets for therapeutic intervention. 
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Results 
 
Effect of AR allele strength on ETV1-induced PIN 
 To test the role of AR in PCa initiation, we examined the effect of variation in AR 
transcriptional strength on ETV1-induced neoplasia. "Humanized" AR (hAR) mice were 
previously engineered by germline knockin to express an AR protein essentially identical to 
human, including either a short (hAR
12Q
), average (hAR
21Q
) or long (hAR
48Q
) polyglutamine tract 
(Q-tract) in the N-terminal domain, modeling the extremes of human variation (Albertelli et al., 
2006). As the mouse Ar lacks a contiguous Q-tract, which is known to affect AR activity, the 
hAR mice more accurately reflect human AR variation and biology. Q-tract length inversely 
correlates with AR transcriptional activity in vitro, seen as altered prostatic gene expression and 
endpoints of androgen action such as seminal vesicle weight (Albertelli et al., 2006; Chamberlain 
et al., 1994; Simanainen et al., 2011). Previously, we showed that AR Q-tract length modifies 
PCa onset, progression and treatment response in the aggressive TRAMP mouse model 
(Albertelli et al., 2008). Thus, variable AR transcriptional activity has the potential to modulate 
the effect of additional oncogenic events and alter the course of disease. 
 To test the interaction of AR with an oncogene activated in human PCa, hAR
12Q
 and 
hAR
48Q
 mice were crossed with ETV1 transgenic (ETV1
Tg
) mice, in which a probasin-derived 
promoter drives androgen-inducible prostatic expression of human ETV1 (Figure 2.1a) (Tomlins 
et al., 2007).  hAR;ETV1
Tg
 male offspring were castrated at 12 weeks (to ablate androgen 
signaling) or left intact, and prostate lobes were microdissected at 24 weeks and compared to 
those of intact non-transgenic hAR controls. Unlike the alobular human prostate, the mouse gland 
is comprised of three paired dorsolateral, ventral and anterior prostate lobes, referred to as DLP, 
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VP and AP, respectively. Morphologically there is not a particular mouse prostate lobe that is 
most similar to the human prostate (Shappell et al., 2004). 
 Histopathological analysis (n = 5-8 lobes per group) revealed PIN and substantial 
hyperplasia in prostates of intact hAR;ETV1
Tg
 mice (Figure 2.1b). Prostates of intact non-
transgenic hAR controls were either normal or showed focal hyperplasia, and castrated 
hAR;ETV1
Tg
 mice had atrophic glands as expected (data not shown). In intact mice, 25% of 
hAR
12Q
;ETV1
Tg
 and 20% of hAR
48Q
;ETV1
Tg
 animals developed PIN by 24 weeks in the VP 
(Figure 2.1b). All of the remaining intact transgenic mice showed hyperplasia in either the DLP 
or VP (Figure 2.1b). Representative examples of each stage are shown in Figure 2.1c. These 
results are consistent with previous reports in which mice overexpressing ETV1 in the prostate 
via transgene or knock-in developed PIN but did not progress to adenocarcinoma (Baena et al., 
2013; Shin et al., 2009; Tomlins et al., 2007). Here we show that the incidence of PIN was not 
affected substantially by AR Q-tract length. 
 
AR regulation is antagonized by overexpression of ETV1 
 Despite driving only early neoplasia, the ETV1 transgene had a pronounced effect on 
prostatic gene expression. The DLP was chosen for analysis because the expression pattern in 
mouse DLP is most similar to that of the human prostate peripheral zone (Berquin et al., 2005), 
where most human PCa arises. Additionally, as shown below in Pten hemizygous mice, the DLP 
harbored substantially more PIN and adenocarcinoma than other lobes (Figure 2.10). In the 
previously reported hAR TRAMP mice, PIN is most apparent in the DLP as well (Albertelli et 
al., 2008). 
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 qRT-PCR analysis showed that the androgen-induced genes Tmprss2, Pbsn and Nkx3-1 
were downregulated in prostates of intact hAR;ETV1
Tg
 mice, similar to the expected decrease in 
castrated controls (Figure 2.2a). Conversely, Clu, which is normally repressed by AR and thus 
upregulated following androgen ablation, was upregulated in prostates of intact ETV1
Tg
 mice as 
well as in castrated mice (Figure 2.2a). Nkx3-1 is a well-established tumor suppressor gene in the 
prostate and a marker of luminal epithelial cell differentiation (Wang et al., 2009). Nkx3-1 null 
mice develop PIN, and Nkx3-1 is frequently downregulated in human PCa (Kim et al., 2002a). 
Its downregulation in hAR;ETV1
Tg
 mice here suggested a role in ETV1-mediated oncogenesis. 
 Examination of global gene expression differences by RNA-seq revealed striking and 
widespread molecular changes in the prostates of hAR;ETV1
Tg
 relative to hAR mice. DLP RNA 
samples were divided into 3 unique pools per group (2 pools for castrate groups), and a library 
was prepared for each pool. Along with samples from the Pten
+/-
 mice (see below), indexed 
libraries were divided across 4 lanes on the Illumina Hi-Seq 2000 for an average of 11.94 million 
reads per library. 95.8% of bases had quality scores ≥ Q30. Principal component analysis of all 
genes in all libraries was performed to gauge overall expression differences between groups. 
Three distinct clusters were observed, with samples segregated by ETV1 transgene and 
castration, while AR genotype had a substantially smaller effect (hAR
12Q 
and hAR
48Q
 samples 
were intermixed), as shown in Figure 2.2b. 
 Differential expression was performed between pairs of groups, or between multiple 
groups using a generalized linear model (GLM). Genes with a false-discovery rate (FDR) of 0.05 
or less were considered significant. When the hAR
12Q
 and hAR
48Q
 mice were analyzed separately, 
1145 and 2419 genes were upregulated and 757 and 2028 genes were downregulated, 
respectively, in transgenics vs. non-transgenics (Figure 2.2a,c). The majority of genes, 943 
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upregulated (82%) and 571 downregulated (75%), were shared among the hAR
12Q
 and hAR
48Q
 
mice (Figure 2.2d), consistent with the principal component plot. However, a greater number of 
genes were significantly altered in the hAR
48Q
 mice. This may be because the weaker hAR
48Q
 is 
more susceptible to perturbation by ETV1 overexpression, resulting in greater differential 
expression in transgenic mice. 
 Using the GLM tools to combine hAR
12Q
 and hAR
48Q
 mice for differential expression, 
2368 genes were upregulated and 2196 downregulated in intact hAR;ETV1
Tg
 relative to hAR 
mice (Figure 2.3a). A comparable number of genes were differentially expressed among the 
castrated mice relative to intact, serving to highlight androgen-regulated genes (whether direct or 
indirect targets) by the effects of androgen ablation (data not shown). Such extensive differential 
expression in castrated mice was expected, but the magnitude of the effect in intact ETV1 
transgenics was striking. The differential expression patterns between transgenic and non-
transgenic DLP revealed that the intact hAR;ETV1
Tg
 mice displayed a pattern similar to that of 
castrated mice, with many expression changes in the same direction (Figure 2.3a). Along with 
the initial qRT-PCR data, this suggested that ETV1 may inhibit normal AR function in a manner 
akin to androgen ablation. However, some ETV1-induced changes were "reverted" by castration 
(middle portion of Figure 2.3a), suggesting that ETV1 also controls a number of non-AR target 
genes. 
 To determine which pathways were altered in hAR;ETV1
Tg
 DLP, functional annotation of 
differentially expressed genes was performed with the Database for Annotation, Visualization 
and Integrated Discovery (DAVID) (Huang Da et al., 2009) (http://david.abcc.ncifcrf.gov). 
"Prostate development" and "prostate morphogenesis" were among the gene ontology (GO) 
terms significantly enriched among ETV1-downregulated genes in intact mice. Relative 
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expression of genes annotated with these GO terms is shown in Figure 2.3b and a complete list 
of enriched GO terms is in Online Resource 2 
(http://link.springer.com/article/10.1007%2Fs12672-014-0215-9) (Higgins et al., 2015). 
Importantly, this gene list includes the tumor suppressors Nkx3-1 and Pten. Furthermore, the AR 
pioneer factor Foxa1 (Gao et al., 2003; Lupien and Brown, 2009) was downregulated in 
hAR;ETV1
Tg
 mice. As downregulation of Pten or Foxa1 would be predicted to result in 
diminished AR transcriptional activity (Carver et al., 2011; Mulholland et al., 2011), the 
expression pattern in hAR;ETV1
Tg
 mice suggests a possible upstream mechanism by which 
ETV1 overexpression could antagonize AR. 
 To examine the significance of these DLP expression differences in the context of human 
cancer, differentially expressed mouse gene sets were converted to human official gene symbols 
and uploaded to Oncomine (Rhodes et al., 2004). The Oncomine database contains thousands of 
"molecular concepts", which are gene sets annotated as being overexpressed in a certain cancer 
subtype, induced by a certain drug treatment, or some other biologically meaningful annotation. 
Mouse gene IDs from significant gene sets were converted to unique human gene symbols using 
the HCOP tool at www.genenames.org, and then uploaded to Oncomine as "custom concepts". 
Each custom concept was queried against the public Oncomine concept database and our custom 
concepts. Notably, genes downregulated in hAR;ETV1
Tg
 mice relative to hAR mice were 
significantly associated with the following concepts: "upregulated genes in prostate cancer cells 
in response to synthetic androgen R1881" (DePrimo et al., 2002), "upregulated genes (time 
dependent) in prostate cancer cells in response to androgen" (Jones et al., 2005), "downregulated 
genes in prostate cancer after androgen ablation therapy" (Holzbeierlein et al., 2004), and custom 
concepts containing genes downregulated in the castrated mice (Figure 2.3c). Similarly, genes 
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upregulated in hAR;ETV1
Tg
 mice relative to hAR mice were significantly associated with the 
concept: "upregulated genes in prostate cancer after androgen ablation therapy" (Holzbeierlein et 
al., 2004) as well as custom concepts containing genes upregulated in the castrated mice (Figure 
2.3c). A complete list of significantly associated concepts can be found in Online Resource 3 
(http://link.springer.com/article/10.1007%2Fs12672-014-0215-9) (Higgins et al., 2015). Thus, a 
significant subset of androgen-responsive genes, including those altered in human PCa patients, 
are affected by the ETV1 transgene in these mice. Furthermore, a large number of muscle-
associated genes were upregulated in the prostates of hAR;ETV1
Tg
 mice (Figure 2.3b). This could 
reflect stromal smooth muscle cell gene expression that is affected in a paracrine manner by 
ETV1 activity in the epithelial compartment, disrupting normal pro-differentiation signals (Singh 
et al., 2014). Finally, ETV1-upregulated genes were significantly enriched for targets of the 
polycomb repressive complex (PRC) (Figure 2.3b). Co-regulation by the PRC, AR and the ETS 
factor ERG has been reported previously, however ERG repressed those shared targets in human 
PCa cells (Yu et al., 2010). These results could indicate divergent functions of ETV1 and ERG, 
their differential action at early vs. late disease stages or discrepancies between in vitro and in 
vivo results. 
 In sum, ETV1 overexpression in mouse prostate antagonized AR transcriptional activity 
and disrupted the normal prostate expression program. This included the repression of important 
prostate tumor suppressors, differentiation genes and AR coregulators as well as derepression of 
polycomb target genes. 
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Pten reduction and ETV1 overexpression cooperate to promote PCa progression 
 ETV1 overexpression was previously shown to exacerbate PCa progression in mice with 
total knockout of Pten in the prostate (Baena et al., 2013). Because many human prostate tumors 
show deletion of only one allele or a partial decrease in expression of PTEN, we asked whether 
reduction of this key tumor suppressor would cooperate with ETV1 overexpression in 
oncogenesis. Further, we queried whether varying AR transcriptional strength would impact 
disease progression. ETV1 transgenic mice carrying short, median or long Q-tract AR alleles 
were backcrossed at least five generations onto the FVB background, and then crossed with FVB 
mice bearing germline deletion of one Pten allele (Pten
+/-
) for optimal genetic homogeneity 
(Figure 2.1a). Cohorts of each genotype were castrated at 12 weeks or left intact, and aged until 
moribund or until PTEN-dependent disease (generally lymphoma (Trotman et al., 2003)) 
necessitated euthanization (median age of 41 weeks, range 20-83 weeks). 
 Pten
+/- 
mice developed more frequent PIN than the Pten
+/+
 mice regardless of ETV1 
transgene or AR allele (Figure 2.4). The majority of intact mice developed PIN, as did a subset 
of castrates. Of note, the hAR
21Q
 mice developed slightly less PIN overall, regardless of the 
ETV1 transgene, and showed no PIN in the absence of androgen. PIN was graded from PIN2 to 
PIN4, with PIN4 being the most severe (Ittmann et al., 2013; Park et al., 2002). Among intact 
mice, progression to adenocarcinoma occurred exclusively in ETV1 transgenics (Figure 2.4). 
Macroscopic DLP tumors were identified upon dissection in one hAR
12Q
 and one hAR
21Q
 mouse. 
Histopathological analysis detected adenocarcinoma in the VP of one additional transgenic 
hAR
12Q
 mouse (Figures 2.10, 2.11). Intriguingly, adenocarcinoma was observed in two castrated 
hAR
12Q
 mice (one with and one without the ETV1 transgene) (Figure 2.4). Castration-resistant 
disease has been observed in TRAMP mice (Albertelli et al., 2008) and in prostate-specific Pten 
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knockout mice (Mulholland et al., 2011), but not in Pten heterozygous animals. These data 
suggest that even a partial reduction in PTEN may be sufficient to promote CRPC. 
 The DLP had markedly greater frequency and severity of neoplasia than the VP among 
intact mice, while among castrated mice the rates of PIN were lower overall but similar between 
lobes (Figure 2.10). There was a trend toward more frequent and severe disease in intact mice 
older than the median age of 41 weeks, while among castrates there was a greater trend for 
disease incidence in mice 41 weeks or younger (Figure 2.10). While it was previously reported 
that ETV1 promoted PCa progression in Pten-null mouse prostates (Baena et al., 2013), these 
results show that ETV1 overexpression cooperated with even partial PTEN loss (see below) to 
promote aggressive PCa. Additionally, these results indicated that even heterozygous PTEN loss 
promoted castration-resistant neoplasia and adenocarcinoma. Furthermore, the stronger AR 
carried by hAR
12Q
 mice promoted greater PCa progression despite similar overall rates of PIN. 
 Immunohistochemical (IHC) staining for AR protein revealed nuclear expression in 
prostate epithelial cells in normal regions as well as in PIN and adenocarcinoma foci, similar to 
human disease where AR is present throughout PCa progression (Figure 2.5). Analysis of ETV1 
expression by RNA in situ hybridization (RNA-ISH), performed by a pathologist blinded to 
genotype, confirmed ETV1 expression in prostate epithelial cells of hAR;ETV1
Tg
;Pten
+/-
 mice 
and undetectable ETV1 expression in non-transgenics (Figure 2.5, 2.11). ETV1 expression 
varied somewhat between individual transgenic animals, with a trend for higher expression in 
mice with more advanced PIN or adenocarcinoma. This could be because high ETV1 expression 
promotes more aggressive disease, or alternatively because AR signaling is partially increased in 
neoplastic cells, resulting in increased expression of the AR-driven ETV1 transgene. 
Interestingly, there was substantial heterogeneity between the two DLP tumors, with the hAR
12Q
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tumor (Figure 2.5, row 4) appearing less differentiated than the hAR
21Q
 tumor (Figure 2.5, row 
5). Thus, in this small sample, adenocarcinoma tended to be more frequent and aggressive in the 
hAR
12Q
 mice. 
 Despite the germline loss of one Pten allele and an approximately 50% reduction in Pten 
mRNA (see below), robust PTEN protein expression was detected in all samples tested. 
However, locally reduced PTEN expression was seen in a subset of PIN and adenocarcinoma 
foci (Figure 2.5). PTEN normally dephosphorylates and inactivates PI3K, in turn preventing 
phosphorylation and activation of Akt and thus inhibiting Akt-mediated cell growth and 
proliferation (Stambolic et al., 1998). Despite maintenance of PTEN protein expression even in 
neoplastic foci, phospho-Akt (pAkt) protein was present exclusively in regions of PIN or 
adenocarcinoma (Figure 2.5). Greater pAkt staining correlated with more advanced disease, as 
expected. Therefore, in this model complete PTEN loss is not necessary for AKT activation. 
 
Reduction of PTEN leads to abrogated effect of ETV1 on AR 
 We next examined the effect of ETV1 on gene expression in this model of PCa 
progression. qRT-PCR analysis of AR target genes Tmprss2, Pbsn, and Nkx3-1 revealed 
markedly attenuated ETV1 influence in prostates of Pten
+/-
 relative to Pten
+/+
 mice (Figure 2.6a, 
note that expression in Pten
+/+
 mice is shown in lanes 1-3 of each gene for reference). However, 
overall repression of AR target genes was observed when one Pten allele was deleted, and those 
targets were still strongly repressed in castrated Pten
+/-
 mice (Figure 2.6a). Prostatic Pten 
expression was indeed about half on the Pten
+/-
 background, and was repressed by ETV1 (or 
castration) in prostates of Pten
+/+
 but not Pten
+/-
 mice (Figure 2.6b). This observation revealed 
that even a partial reduction in prostatic PTEN inhibited AR, extending a previous finding that 
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total PTEN loss in the prostate leads to reduced AR activity (Carver et al., 2011; Mulholland et 
al., 2011). 
 To further compare the molecular effects of hAR allele and ETV1 overexpression in the 
Pten
+/-
 background, global gene expression was analyzed by RNA-seq. DLP RNA samples from 
ETV1 transgenic vs. non-transgenic mice as well as from the individual macroscopic tumors 
were assayed. Principal component analysis of the RNA-seq data showed that samples from all 
castrated mice and one macroscopic tumor clustered together (Figure 2.7a). The remaining tumor 
from a hAR
12Q
 mouse mapped separately, suggesting a disparate expression pattern, as might be 
expected from the poorly differentiated phenotype (see Figure 2.5). Samples from intact mice 
showed substantial heterogeneity within and between groups and did not form distinct clusters 
regardless of the transgene, suggesting that ETV1 had a more moderate and/or variable effect in 
this background (Figure 2.7a). 
 Overall, fewer genes were significantly differentially expressed between the prostates of 
transgenic and non-transgenic mice on the Pten
+/- 
background. 59 genes were upregulated and 3 
downregulated when all intact transgenics were contrasted with all intact non-transgenics by 
GLM analysis (Figure 2.7b). Interestingly, this set was enriched with 15 genes also upregulated 
by ETV1 in the Pten
+/+
 mice, including orthologs of the PCa-associated genes PSCA, SOX4 and 
HPN (Figure 2.7c). In particular, HPN is highly overexpressed in human PCa, promotes 
metastasis in a mouse model, and can be effectively targeted with a small molecule inhibitor 
(Tang et al., 2014). Additionally, these 59 genes were enriched for genes further upregulated in 
the macroscopic DLP tumors (see below), suggesting that ETV1 induces oncogenic expression 
changes prior to invasive disease, and that these genes may serve as biomarkers of impending 
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tumorigenesis. Androgen ablation affected a similar number of genes as in the Pten
+/+
 mice (data 
not shown). 
 In contrast to little apparent effect of Q-tract length on the Pten
+/+
 background (see 
Figure 2.2a), separating the groups by hAR allele revealed notable differences in expression due 
to androgen axis variation in Pten
+/-
 mice. Analysis of individual hAR genotypes revealed 39, 
156 and 303 genes upregulated and 180, 51 and 30 genes downregulated between transgenic and 
non-transgenic hAR
12Q
, hAR
21Q
 and hAR
48Q
 prostates, respectively (Figures 2.7d, 2.12). Unlike in 
the Pten
+/+
 background, the majority of differentially expressed genes showed little overlap, 
indicating they were unique to a single hAR genotype. There was a general trend toward greater 
repression by ETV1 in the context of the stronger hAR
12Q
 allele, and greater activation by ETV1 
with the weaker hAR
48Q
 allele. Fewer differences in gene expression between ETV1-transgenic 
and non-transgenic Pten
+/-
 mice could result in part from larger variance in age and disease stage 
among mice, or more heterogeneous ETV1 effects overall, in turn resulting in the variation seen 
in Figure 2.7b and thus reduced statistical sensitivity. Additionally, ETV1 could have a directly 
reduced influence on gene expression on the Pten
+/-
 background. This latter explanation is 
supported by the qPCR data (Figure 2.6a), suggesting an abrogation of the effect of ETV1 on AR 
targets. Concept mapping confirmed that the broad ETV1-AR antagonism observed in the 
Pten
+/+
 mice was diminished by loss of one Pten allele (Online Resource 3, Higgins et al., 2015). 
  
ETV1 induced inflammatory gene expression 
 Genes upregulated in prostates of ETV1-transgenic vs. nontransgenic hAR;Pten
+/-
 mice 
were significantly enriched with inflammation-associated GO terms (Figure 2.7a). Relative 
expression of these genes is illustrated in the heatmap of Figure 2.8a, including expression levels 
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in the macroscopic DLP tumors. Many of the inflammatory genes were upregulated further in 
one or both tumors. The chemokines CXCL5 and CXCL16 are known to be associated with 
human PCa progression (Begley et al., 2008; Jung et al., 2013), and NUPR1 is associated with a 
variety of cancers including breast, pancreatic and lung cancer (Guo et al., 2012; Hamidi et al., 
2012; Jung et al., 2012). Because a significant inflammation signature was seen in prostates of 
ETV1 transgenic mice prior to overt tumorigenesis, it is possible that ETV1-dependent 
inflammation may contribute to oncogenesis. Regardless, these factors may be biomarkers of 
impending tumorigenesis in ETV1
+
 prostates. In support of the functional significance of this 
gene signature, histologic evidence of inflammation has been previously noted in ETV1 knockin 
mice (Baena et al., 2013). 
 Direct ETV1 regulation of CXCL16 and NUPR1 was tested in human prostate cells. The 
benign human prostate epithelial cell line RWPE-1 was transduced with lentiviral vectors that 
stably express AR, as well as either ETV1 or LACZ (Tomlins et al., 2007; Tomlins et al., 
2008a). qRT-PCR revealed that the ETV1-transduced cells expressed the endogenous CXCL16 
and NUPR1 genes at significantly higher levels than the LACZ controls (Figure 2.8b), providing 
evidence of direct gene regulation by ETV1. This upregulation was observed with or without 
stimulation with the synthetic androgen R1881, suggesting that ETV1 induction of CXCL16 in 
these cells is not AR-dependent. In contrast, NUPR1 was sensitive to androgen in the absence 
but not the presence of exogenous ETV1. 
 
ETV1 effects in mouse DLP parallel those in ETS
+
 and aggressive human PCa 
 We explored the significance of these data by comparison to human PCa expression 
patterns and sought novel ETV1-regulated genes.  Molecular concept analysis in Oncomine 
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revealed significant overlap between androgen-induced genes (see Figure 2.3), genes 
downregulated in DLP tumors and genes downregulated by ETV1 in Pten
+/+
 mice. Relative 
expression of these shared genes is shown in the heatmap in Figure 2.9a. This pattern suggests 
that expression patterns in late ETV1/PTEN-induced tumorigenesis recapitulate early ETV1-
induced signatures. Thus, selective AR repression may be important at multiple disease stages. 
Notably, the tumor suppressor and luminal epithelial differentiation marker Nkx3-1 (Wang et al., 
2009) is among androgen-induced transcripts downregulated in the tumors as well as prostates of 
early-stage ETV1
Tg
 mice. Genes differentially expressed in ETV1
Tg
;Pten
+/-
 prostates were not 
significantly enriched for this set of androgen-induced genes, yet overlapped with early-stage 
mouse disease, DLP tumors and human PCa (see Figs. 7 and 8). When genes differentially 
expressed in the macroscopic DLP tumors were further queried in Oncomine, significant 
enrichment with aggressive human PCa was observed. Genes downregulated in the 
hAR
21Q
;ETV1
Tg
;Pten
+/-
 DLP tumor were significantly enriched for downregulated genes in 
human PCa metastases and advanced Gleason grade tumors (Figure 2.9b) (Grasso et al., 2012; 
Holzbeierlein et al., 2004; Lapointe et al., 2004; Nakagawa et al., 2008; Yu et al., 2004). 
 Two recent large-scale studies profiled gene expression in localized and metastatic PCa 
from over 200 total patients (Grasso et al., 2012; Taylor et al., 2010). These microarray data 
were stratified by ETS status, PTEN expression level and localized vs. metastatic tumors, and 
compared with the mouse RNA-seq data. Molecular concept analysis of the dataset from Taylor, 
et. al., with ERG
+
 and ETV1
+
 patients combined as "ETS
+
", revealed that genes downregulated 
in ETS
+
, PTEN-normal localized tumors vs. non-ETS tumors were significantly enriched among 
genes downregulated in prostates of hAR;ETV1
Tg
 mice or in DLP tumors (Figure 2.9c). While 
many transcripts were present in patterns unique to DLP tumors or hAR;ETV1
Tg
 prostates, a 
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number were repressed in both groups (Figure 2.9c, middle horizontal rows). As with important 
androgen-regulated genes (see Figure 2.9a), this overlap once again suggests common ETV1 
action in early neoplasia and in tumors, in contrast to intermediate stages of tumorigenesis. 
 Genes downregulated in ETS
+
 patients that are also downregulated in hAR;ETV1
Tg
 mice 
as well as DLP tumors include a number of genes associated with various cancers, but not yet 
with PCa (Figure 2.9c). For example, REC8 is a meiotic recombination gene whose 
hypermethylation is associated with poor prognosis in gastrointestinal stromal tumors (Okamoto 
et al., 2012). Downregulation of the stromal cell-derived factor 2-like 1 (SDF2L1) gene is 
associated with poor prognosis in breast cancer (Kang et al., 2009). SEMA4G was one of the few 
candidate tumor suppressor genes on the colorectal cancer (CRC) associated chromosome 10 
loss of heterozygosity (LOH) region to be significantly downregulated in CRC tumors (Wang et 
al., 2008). This suggests potential roles for these genes in PCa, and potential regulation by ETS 
factors. 
 Of note, several genes were dysregulated in opposite directions in the two DLP tumors, 
including H19, SEMA4G and KCNN4 (Figure 2.9c,d). This highlights the heterogeneity between 
the tumors and among these mice in general, similar to heterogeneity among human PCa 
patients. Furthermore, many genes were repressed in hAR;ETV1
Tg
 mice but upregulated in DLP 
tumors, or vice-versa (Figure 2.9c). This pattern emphasizes that while there is substantial 
overlap between early and late stages, as described above, there is a great deal of divergence as 
well, and different ETV1 targets may be more important or play different roles at one stage of 
disease progression than another. 
 PCa patient expression data from the study by Grasso et. al. (Grasso et al., 2012) was 
stratified as above by ETS status, PTEN expression level and localized vs. metastatic tumor site, 
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and differential expression was re-calculated. Overlap with the mouse RNA-seq data is shown in 
Figure 2.9d. KCNN4, a potassium channel gene, was upregulated in localized ETV1
+
 vs. ETS
-
 
tumors in human PCa patients with normal PTEN levels (Grasso et al., 2012), as well as in 
hAR;ETV1
Tg
 vs. prostates and in DLP tumors (Figure 2.9d). KCNN4 expression is increased in 
benign prostatic hyperplasia (BPH) and intermediate Gleason grade PCa, but not high Gleason 
grade PCa (Ohya et al., 2009; Ohya et al., 2011). Additionally, LRP8, a low density lipoprotein 
receptor, is upregulated in localized ETV1
+
 human tumors with normal PTEN (Grasso et al., 
2012) and in mouse DLP tumors (Figure 2.9d). High LRP8 expression is associated with several 
human cancers, including lung and gastric cancer, but has not yet been linked to PCa (Dun et al., 
2013; Garnis et al., 2005; Pencheva et al., 2012). As before, these genes showed variable 
upregulation between the DLP tumors, highlighting heterogeneity in mouse as well as in human 
patients. 
 Expression in the intermediate-stage ETV1
Tg
/Pten
+/-
 mice showed little overlap with the 
human data in these particular comparisons. In part, this could be due to fewer differentially 
expressed genes at that intermediate stage (see above). However, as seen in Figures 2.7 and 2.8, 
ETV1 induced a notable inflammatory signature in Pten-hemizygous mice, along with a number 
of individual PCa-associated genes and genes shared with both the early ETV1
Tg
 mice and the 
later DLP tumors. In sum, these studies shed light on distinct ETV1 gene regulatory networks at 
different disease stages, and highlight novel ETV1 targets when filtered against human data. 
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Discussion 
 
 This study examined in mice the degree to which AR genetic variation and ETV1 
overexpression interact early in neoplasia, and their subsequent interaction with PTEN reduction 
in PCa progression. In both patients and transgenic mice, ETS overexpression is AR-driven, and 
AR activity is affected by factors downstream of PTEN. The molecular consequences of altering 
AR and ETV1 transcriptional regulation was queried with high-throughput gene expression 
analysis. Marked antagonism of the normal AR-regulated transcriptome occurred in prostates of 
ETV1 transgenic mice despite mild pathology. This antagonism was largely abrogated on a Pten-
hemizygous background. In the Pten-hemizygous mice concurrent ETV1 overexpression induced 
progression to adenocarcinoma in a subset of mice as well as a striking pro-inflammatory gene 
signature. AR variation had little impact on early neoplasia driven by ETV1, but a stronger AR 
allele impacted gene expression and PCa progression in the Pten-hemizygous model. These 
results suggest that ETV1 cooperates with even reduced PTEN signaling to drive cancer 
progression in mice, and that partially antagonizing AR and promoting inflammation may be key 
components of the ETV1-driven oncogenic program. Integration of mouse and patient data 
revealed potential ETV1 regulation of known and novel PCa-associated genes, suggesting novel 
targets for therapeutic intervention. 
 Despite substantial AR antagonism similar to the effects of castration, prostates of 
ETV1
Tg
 mice do not show atrophy, suggesting selective action favoring survival and 
proliferation. While ETV1 overexpression is insufficient to cause invasive PCa in mice, 
disruption of the normal AR-regulated, pro-differentiation gene expression program drives PIN 
and hyperplasia. This may "prime" the prostate for further dedifferentiation and tumor 
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progression following additional oncogenic insults, such as PTEN reduction or loss. In the case 
of ERG, it has been reported that PTEN loss is correlated with ERG fusions in patients (King et 
al., 2009) and that ERG fusion precedes PTEN loss (Gumuskaya et al., 2013). 
 We have previously shown an influence of the androgen axis on PCa onset and 
progression in TRAMP mice, where oncogenesis is driven by prostatic expression of an SV40 
Large-T antigen transgene (Albertelli et al., 2008). While AR strength does not impact the early 
stages of ETV1-induced neoplasia in the current model, the rate of progression to 
adenocarcinoma is impacted when combined with Pten reduction. Confirmation here of the 
influence of AR in a model reflecting recurrent events in human PCa adds to the recent discovery 
that ETS
+
 PCa is more common in men with a stronger AR (Yoo et al., 2014). 
 While fewer genes are affected by ETV1 overexpression in the Pten
+/-
 background 
overall, a greater number of differentially expressed genes are identified when Q-tract variants 
are analyzed individually, revealing divergent effects of the androgen axis on gene expression 
and disease progression. The hAR
12Q
 mice show significant repression of polycomb target genes 
with ETV1 overexpression, as do the DLP tumors, where most other groups show the opposite 
pattern (Online Resource 3, Higgins et al., 2015). As ETS factors can interact with the polycomb 
repressive complex (Yu et al., 2010), perhaps the greater repression seen with hAR
12Q
 indicates a 
greater cooperation in the context of the stronger AR and low PTEN, and could signify 
impending tumorigenesis. Induction of inflammatory genes is more pronounced in the hAR
21Q
 
and hAR
48Q
 mice (Online Resources 2 and 3, Higgins et al., 2015). A number of those 
inflammatory genes are further upregulated in the tumors, indicating that they may be potential 
early biomarkers of aggressive disease. While a number of mouse models of PCa show 
inflammation during tumorigenesis, the expression signature specifically in ETV1
Tg
 mice relative 
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to non-transgenics suggests a role of ETV1. Confirmation of regulation by ETV1 in vitro 
supports inflammation as a factor in ETV1
+
 neoplasia. 
 A "core" set of targets is upregulated by ETV1 in both Pten
+/+
 and Pten
+/-
 mice, 
including a number of genes known to be upregulated in human PCa. Several of these genes 
including PSCA and HPN encode proteins that are druggable in vitro and in preclinical models 
(Tang et al., 2014; Yu et al., 2013). ETS
+
 patients with particularly high expression of these 
genes may respond more favorably in future targeted therapy. ERG promotes SOX4 expression 
to stimulate epithelial to mesenchymal transition in PCa (Wang et al., 2014), and these mouse 
data suggest that ETV1 may promote SOX4 expression as a common component of ETS-driven 
oncogenesis. 
 Combined inhibition of the AR and PI3K/AKT pathways in PCa has been recently shown 
to be a potentially effective treatment strategy, as these pathways reciprocally repress one 
another, and either pathway can compensate when the other is inhibited (Carver et al., 2011; 
Mulholland et al., 2011). Since the AR, PTEN and ETV1 pathways all cooperate in PCa 
progression, dual inhibition of AR and PI3K/AKT may be more effective for some patients 
following stratification by ETS fusion status. 
 The CRPC seen in castrated Pten-hemizygous mice highlights the fact that hormone 
ablation generally slows disease progression in mice and patients, but in some cases can 
accelerate it (Albertelli et al., 2008; Johnson et al., 2005). In the previous TRAMP study, CRPC 
varied with AR strength, with half of castrated hAR
12Q
 mice failing to evince a palpable tumor 
prior to dying of metastatic castrate-resistant disease (Albertelli et al., 2008). Not only did a 
number of castrated Pten-hemizygous mice develop PIN or adenocarcinoma, but disease tended 
to arise earlier than in the intact mice, and greater progression was seen with the stronger hAR 
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allele. While CRPC has been previously reported in mice with a prostate-specific Pten deletion, 
these results suggest that even Pten reduction can promote CRPC. These findings support 
clinical data that hemizygous PTEN deletion predicts more rapid disease recurrence following 
radical prostatectomy and hormone therapy (Choucair et al., 2012). Further, this raises the 
question of whether AR genotyping might have predictive value in these situations. 
 Whether ETS fusion status in patients is associated with poor prognosis remains 
controversial and depends heavily on cohorts studied and definitions of disease aggressiveness 
(Rubin et al., 2011; Taris et al., 2014b). Results from the current study suggest that a stronger 
AR promotes ETV1-driven PCa progression, in line with the androgen regulation of the 
transgene in mice and of fusion genes in patients. Castration eliminates ETV1-driven disease in 
Pten
+/+
 mice, and significantly reduces overall disease in Pten
+/-
 mice. In one study, a subset of 
ERG
+
 patients had a very favorable response to abiraterone acetate, which targets androgen 
synthesis via CYP17 inhibition (Attard et al., 2009). This underscores the androgen regulation of 
ETS fusion genes, and suggests that those tumors may be more dependent on AR activity than 
fusion-negative tumors. 
 Genes downregulated in the DLP tumors relative to PIN show the same expression 
pattern in high Gleason grade and metastatic human PCa (see Figure 2.9b). This finding suggests 
that the genes and pathways altered in the mouse models described here are not only generally 
relevant to human PCa, but may indicate aggressive disease. Genes downregulated in DLP 
tumors are enriched for androgen-induced targets, and in particular those that are also repressed 
by ETV1 in prostates of Pten
+/+
 mice. These data suggest that the selective antagonism of AR in 
early neoplasia becomes a redirection of AR activity in later stage tumorigenesis. 
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 Direct comparison of the mouse data to several human PCa patient data sets stratified by 
ETS status and PTEN expression level (Grasso et al., 2012; Taylor et al., 2010) reveal a number 
of known and novel PCa-associated genes potentially regulated by ETV1. One of these, KCNN4, 
is targetable with a potassium channel inhibitor in a rat model of BPH (Ohya et al., 2011), 
suggesting that it may have utility in ETV1
+
 PCa patients. Additional genes including LRP8, 
SEMA4G, REC8 and SDF2L1 are associated with other cancers but not yet PCa, and not yet with 
ETS regulation (Dun et al., 2013; Garnis et al., 2005; Kang et al., 2009; Okamoto et al., 2012; 
Pencheva et al., 2012; Wang et al., 2008). H19 has a known role in PCa (Zhu et al., 2014) but no 
known ETS regulation. These data suggest potentially novel roles for these genes in PCa, as well 
as regulation by ETV1, warranting their further exploration as biomarkers or in therapeutic 
strategies. 
 Recently, ERG overexpression was shown to have little effect on AR signaling in the 
mouse prostate, but after Pten deletion ERG enhanced AR activity and stimulated tumorigenesis 
(Chen et al., 2013). The same effect was observed in human PCa expression sets stratified by 
these factors, with ERG-AR cooperation found in PTEN-low tumors (Chen et al., 2013). In vitro, 
ERG is a strong repressor of AR in several PCa cell lines with or without functional PTEN (Yu 
et al., 2010).  Further data show that ERG blocks AR-induced differentiation in luminal 
epithelial cells (Mounir et al., 2014; Tomlins et al., 2008a). These studies suggest that the ERG-
AR interaction is context-dependent, with different outcomes observed in vitro and in vivo, and 
dependent on PTEN status and cancer stage. Based on findings here, ETV1 also appears to 
behave in a highly context-dependent manner. In part, our in vivo AR-ETV1 results fall along a 
similar "spectrum" as the AR-ERG interaction described by Chen, et. al. (Chen et al., 2013). 
However, we observe ETV1 antagonism of AR that is lost with reduced Pten, yet in the DLP 
55 
 
tumors strong repression of AR targets recurs. The different interactions could result from PTEN 
dose (hemizygous vs. prostate-specific knockout) or reflect distinct properties of ETV1 vs. ERG. 
ETV1 has been reported to enhance AR activity in vitro (Baena et al., 2013; Chen et al., 2013; 
Shin et al., 2009). However, such studies have been limited to LNCaP cells, which lack 
functional PTEN. Further investigation of the AR-ETV1 interaction in additional models is 
needed to clarify the effect in vivo vs. in vitro, as well as the influence of AR variation and 
PTEN status. 
 In conclusion, the mouse models described here provide novel insight into the interaction 
of key pathways driving early-intermediate stage PCa, and also reflect aggressive human disease. 
A role of the androgen axis in disease progression is confirmed in PCa models driven by 
recurrent somatic genetic alterations seen in patients. A number of known and druggable PCa-
associated factors show potential ETV1 regulation and warrant further investigation in patients 
stratified by AR, ETS and PTEN status as novel therapeutic targets or prognostic biomarkers. 
 
Materials and Methods 
 
Mice 
 All animal work was performed in accordance with protocols approved by the University 
Committee on Use and Care of Animals (UCUCA) at the University of Michigan. ETV1-
transgenic FVB mice expressing the human ETV1 coding region driven by the ARR2-Pb 
promoter (ETV1
Tg
) were a gift from Dr. Arul Chinnaiyan (University of Michigan) (Tomlins et 
al., 2007). In the first experimental cohort, ETV1
Tg
 males were crossed with C57BL/6 females 
expressing a "humanized" androgen receptor (hAR) (Albertelli et al., 2006) with a short (12Q) or 
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long (48Q) polyglutamine tract. Transgenic males (hAR;ETV1
Tg
) were castrated at 12 weeks or 
left intact, and aged to 24 weeks. Intact, non-transgenic hAR mice were used as controls. For the 
second series, Pten
flox/flox
 mice (Lesche et al., 2002), on an FVB background, a gift from Dr. 
William Muller (McGill University), were crossed with FVB/N-Tg(EIIa-cre)C5379Lmgd/J mice 
(Jackson Labs # 003314) to excise the floxed Pten. Pten-deleted offspring were maintained as 
hemizygotes (Pten
+/-
). hAR;ETV1
Tg
 mice carrying 12Q, 21Q or 48Q hAR alleles were 
backcrossed for at least five generations onto the FVB background and then female transgenics 
crossed with Pten
+/-
 males. Resulting hAR;ETV1
Tg
;Pten
+/-
 and hAR;Pten
+/-
 males were either 
castrated at 12 weeks or left intact, and aged to a median of 41 weeks (range 20-83 weeks). 
Genotyping primers are listed in Table 2.1. 
 
Microdissection and sample preparation 
 Anterior prostate (AP), dorsolateral prostate (DLP) and ventral prostate (VP) lobes were 
individually microdissected from experimental mice. For the hAR;ETV1
Tg
 mice, lobes were 
frozen in Optimal Cutting Temperature (OCT) compound (Sakura). 5 μm sections were cut and 
stained with hematoxylin and eosin (H&E) for histology, and RNA was extracted from the 
remaining tissue (see below). For hAR;ETV1
Tg
;Pten
+/-
 mice, one lobe per pair was fixed in 10% 
neutral-buffered formalin for 24 hours, then transferred to 70% ethanol until embedding in 
paraffin and cutting of 5 μm sections for H&E staining. The other lobe was frozen in RNA-later 
(Ambion). All prostate RNA was purified with the RNeasy kit with on-column DNase digestion 
(Qiagen) following tissue homogenization in Buffer RLT. Macroscopic prostate tumors were 
divided in half, with one half prepared for histology and the other half prepared for RNA 
analysis as described above. 
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qRT-PCR 
 cDNA was reverse-transcribed from total RNA using random hexamers and either the 
SuperScript II 1st-Strand Synthesis kit (Invitrogen) for mouse prostate RNA, or the High 
Capacity cDNA Reverse Transcription kit (Applied Biosystems) for human cell line RNA. qRT-
PCR samples were run on an AB7300 or AB7500 thermal cycler (Applied Biosystems) using 
Power SYBR Green Master Mix (Applied Biosystems) or ABSolute Blue SYBR Green Rox 
Master Mix (Thermo Scientific) according to the manufacturer's instructions. Following 
normalization to Actb for mice, and ACTB or GAPDH for human cells, relative expression was 
calculated using the 2
-ΔΔCt
 method. All primer sequences are listed in Table 2.1. 
 
RNA-seq analysis 
 Mouse DLP RNA was used for Illumina mRNA-seq library construction. For each 
genotype/treatment group (n = 4-13 mice per group), individual RNA samples were divided 
amongst 3 unique pools (2 unique pools for castrated groups due to low RNA yield) and a library 
was prepared from each pool. Individual libraries were prepared for each macroscopic DLP 
tumor as well (n = 2). For each library, poly-A
+
 RNA was first purified from 200 ng total RNA 
with Dynabeads Oligo(dT)25 (Invitrogen). Libraries were constructed with NEBNext mRNA-seq 
Master Mix reagents and NEBNext Multiplex Oligos for Illumina (New England Biolabs). 
Multiplexed libraries were sequenced on an Illumina HiSeq 2000 with the SE-50 module at the 
University of Michigan Sequencing Core. Four lanes were sequenced, each containing 11-12 
indexed libraries. Reads were aligned to the mouse mm10 genome with TopHat2 (Kim et al., 
2013), transcript counts were generated with the HT-Seq Python script (http://www-
huber.embl.de/users/anders/HTSeq/doc/index.html) and differential expression was calculated in 
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the Bioconductor package edgeR, which utilizes counts rather than FPKM (Anders et al., 2013). 
Contrasts were performed between pairs of genotype/treatment groups, or between multiple 
genotype/treatment groups using the generalized linear model (GLM) tools in edgeR. Genes 
differentially expressed at a false-discovery rate (FDR) ≤ 0.05 were considered significant. 
 
Bioinformatics functional annotation and pathway analysis 
 Functional annotation of significant gene sets was performed with DAVID 
(http://david.abcc.ncifcrf.gov) (Huang Da et al., 2009). The following gene ontology (GO) terms 
and pathways were tested for enrichment: GOTERM_BP_ALL, GOTERM_CC_ALL, 
GOTERM_MF_ALL, PANTHER_BP, PANTHER_MF, BIOCARTA, KEGG_PATHWAY and 
PANTHER_PATHWAY. GO terms and pathways with a Benjamini-adjusted FDR ≤ 0.05 were 
considered significantly enriched relative to the Mus musculus background gene list. 
 Enrichment with human cancer-related gene sets was performed with Oncomine 
(https://www.oncomine.org) (Rhodes et al., 2004). Mouse gene IDs from significant gene sets 
were converted to unique human gene symbols using the HCOP tool at www.genenames.org, 
and uploaded to Oncomine as "custom concepts". For gene sets with more than 1000 genes, the 
top 1000 were used for custom concepts. Each custom concept was queried against the "Biology 
Concepts", "My Concepts", "Literature-defined Concepts" and "Oncomine Gene Expression 
Signatures" concept databases in Oncomine with "All Entrez Genes" as the background list. 
Significant enrichment was set as an odds ratio (OR) ≥ 4 and a p-value ≤ 10-6. Oncomine output 
was used to generate molecular concept maps (Rhodes et al., 2007) in Cytoscape 
(www.cytoscape.org), with edges representing significant enrichment between concepts and 
node size proportional to overlap with the primary custom concept. 
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Pathological analysis of mouse prostates 
 Mouse prostate lesions were classified and graded based on the recent consensus criteria 
established by the Mouse Models of Human Cancer prostate pathology committee (Ittmann et 
al., 2013; Park et al., 2002). 
 
Immunohistochemistry 
 Slides were prepared with 5 μM sections from FFPE mouse prostates. The antibodies 
used in this study included AR N-20 (Santa Cruz # sc-816, 1:500 dilution), phospho-AKT 
(Ser473) (Cell Signaling #9271, 1:100 dilution), and PTEN (Cell Signaling #9188, 1:80 
dilution). Immunohistochemistry (IHC) was performed essentially as described for AR and 
pAKT (Albertelli et al., 2008), and for PTEN (Bhalla et al., 2013; Sathyanarayana et al., 2014). 
 
In situ hybridization 
 A custom RNA probe against human ETV1 transcript (Advanced Cell Diagnostics) was 
hybridized to 5 μM FFPE mouse prostate sections essentially as described (Kunju et al., 2014). 
 
Cell Lines 
 RWPE-1 cells stably overexpressing ETV1 or LACZ (Tomlins et al., 2007; Tomlins et 
al., 2008a) were a gift from Dr. Arul Chinnaiyan (University of Michigan) and were maintained 
in KSFM (Gibco # 10724-011) supplemented with BPE and EGF, 1:100 penicillin/streptomycin 
(Gibco # 15140-122) and 3 μg/ml blasticidin (Life Technologies # R21001) to maintain stable 
expression of the transduced ETS construct or control. 293T cells were a gift from Dr. Margaret 
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Gnegy (University of Michigan) and were maintained in DMEM (Gibco # 11995-065) with 10% 
FBS (GeneMate # S-1200-500) and 1:100 penicillin/streptomycin. 
 
Lentiviral Packaging and Transduction 
 The FG9 lentiviral expression plasmid was previously derived from FUGW (Addgene # 
14883) (Lois et al., 2002; Qin et al., 2003) and was a gift from Dr. David Baltimore (California 
Institute of Technology). FG9 was linearized with BamHI, and a BglII-3xFLAG-BamHI 
fragment was inserted, destroying the 5' BamHI site but preserving the 3' site. AR was excised as 
a BamHI fragment from the pCMV5-AR plasmid (Steinkamp et al., 2009) and ligated into FG9-
3xFLAG to produce the final FG9-3xFLAG-AR plasmid.  For transduction, 5x10
6
 293T cells 
were seeded in a poly-L-lysine coated 10 cm dish. The following day, cells were transfected with 
10 μg FG9-3xFLAG-AR plasmid or FG9-vector control, 3 μg pHCMVG, 2 μg pRSV-rev, 6 μg 
pRRE and 80 μg polyethylenimine, suspended in 150 mM NaCl. Virus-containing medium was 
harvested 48 and 72 hours post-transfection, filtered through a 0.45 μM filter and applied directly 
to RWPE-ETV1 or RWPE-LACZ cells. After transduction of the AR construct, 100 μg/ml 
Hygromycin B (Life Technologies #10687-010) was added to maintain expression of AR or the 
vector control. 
 
Androgen Stimulation and RNA Purification 
 5x10
4
 RWPE-ETV1-AR or RWPE-LACZ-AR cells were seeded in 12-well dishes in 
complete growth medium without antibiotic selection. Beginning the following day, cells were 
deprived of BPE for 48 hours. Cells were then stimulated with 1 nM R1881 or methanol vehicle 
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for 24 hours before lysis and RNA purification with TRIzol reagent (Ambion # 15596018). The 
experiment was performed in biological triplicate. 
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Table 2.1  Primer sequences for genotyping and real-time PCR 
 
Mouse Genotyping Primers 
Primer sequence 5'-3' 
Qtract.g F ACCCAGAGGCCGCGAGCGC 
Qtract.g R GCACTCCAGGGCCGACTGCG 
ETV1.g F GCCAACTGGGATGCAAGACACT 
ETV1.g R AGAAAGCTGGCGGCGAAATC 
Pten.g 1 ACTCAAGGCAGGGATGAGC 
Pten.g 2 AATCTAGGGCCTCTTGTGCC 
Pten.g 3 GCTTGATATCGAATTCCTGCAGC 
  Mouse qRT-PCR Primers 
Primer sequence 5'-3' 
Pbsn F AGGGACTAAGTGCCAACTGTA 
Pbsn R ACTCCAGCCACTCGTGTGA 
Tmprss2 F CAGTCTGAGCACATCTGTCCT 
Tmprss2 R CTCGGAGCATACTGAGGCA 
Nkx3-1 F GACTGTGAACATAATCCAGGGG 
Nkx3-1 R TGATGGCTGAACTTCCTCTCC 
Clu F TCCCGGAAGTGTGTAACGAGA 
Clu R CGCCGTTCATCCAGAAGTAGA 
Pten F TGCACAGTATCCTTTTGAAGACC 
Pten R GAATTGCTGCAACATGATTGTCA 
hAR F AAGCACTGCTGCTCTTCAGC 
hAR R GAACTGATGCAGCTCTCTTGC 
Actb F AGTGTGACGTTGACATCCGTA 
Actb R GCCAGAGCAGTAATCTCCTTCT 
  Human qRT-PCR Primers 
Primer sequence 5'-3' 
CXCL16 F GCAGCGTCACTGGAAGTTG 
CXCL16 F ATCCCCGAGTAAGCATGTCC 
NUPR1 F ATGGCCACCTTCCCAC 
NUPR1 R TCAGCGCCGTGCCCCTCG 
ACTB F CAAAGACCTGTACGCCAACA 
ACTB R TCAGGAGGAGCAATGATC 
GAPDH F TGCACCACCAACTGCTTAGC 
GAPDH R GGCATGGACTGTGGTCATGAG 
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Figure 2.1: Effect of AR allele strength on ETV1-induced PIN 
 A) C57BL/6 mice carrying a “humanized” AR gene with a short (hAR12Q) or long 
(hAR
48Q
) polyglutamine tract were crossed with ETV1-transgenic FVB mice (ETV1
Tg
) to 
generate hAR;ETV1
Tg
 mice. Experimental mice were castrated or left intact at 12 weeks, aged to 
24 weeks and compared to intact hAR controls. hAR;ETV1
Tg
 mice were then backcrossed to FVB 
and crossed with Pten
+/-
 mice to generate hAR;ETV1
Tg
;Pten
+/-
 experimental mice with short 
(12Q), median (21Q) or long (48Q) Q-tracts. Experimental hAR;ETV1
Tg
;Pten
+/-
 mice were 
castrated or left intact at 12 weeks, aged to an average of 43 weeks and compared to hAR;Pten
+/-
 
controls. B) Representative H&E stained prostates from hAR;ETV1
Tg
 mice. Normal tissue (DLP), 
hyperplasia (DLP) and mPIN (VP) are shown. Images are 10x with 40x insets. c The proportion 
of mice with hyperplasia and mPIN in AP, DLP and VP among hAR
12Q
;ETV1
Tg
 and 
hAR
48Q
;ETV1
Tg
 mice. 5-8 lobes per group were analyzed.  
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Figure 2.2: ETV1 overexpression alters prostatic gene expression 
 A) 2 unique pools of DLP RNA from each group were analyzed by qRT-PCR. 
Expression of the AR target genes Pbsn, Tmprss2, Nkx3-1 and Clu was normalized to Actb 
expression and plotted relative to the intact hAR
12Q
 group using the 2
-ddCt
 method. Mean +/- SEM 
are plotted. B) Principal component analysis was performed for all genes among the 16 
individual RNA-seq libraries. hAR
12Q
 and hAR
48Q
 mice are represented as triangles and circles, 
respectively. Green, red and blue represent intact non-transgenic, intact transgenic and castrated 
transgenic mice, respectively. C) RNA-seq analysis was performed on DLP RNA. Samples from 
intact groups were divided into 3 unique RNA pools for library construction (2 unique pools for 
castrated groups). Heatmaps include differentially expressed genes between the groups shown 
(FDR ≤ 0.05). Individual libraries are shown for differentially expressed genes among intact 
hAR
12Q
;ETV1
Tg
 vs. hAR
12Q
 (1145 up, 757 down) or intact hAR
48Q
;ETV1
Tg
 vs. hAR
48Q
 (2419 up, 
2028 down). Red and blue represent high or low expression, respectively, relative to the mean 
expression level in the samples shown. Columns and rows represent samples and genes, 
respectively. D) Overlap between genes differentially expressed in hAR
12Q
;ETV1
Tg
 and 
hAR
48Q
;ETV1
Tg
 is illustrated by Venn diagram. 
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Figure 2.3: AR regulation is antagonized by ETV1 overexpression 
 A) The generalized linear model (GLM) tools in edgeR were used to test differential 
expression between all hAR;ETV1
Tg
 and all hAR mice. 2368 genes were upregulated and 2196 
downregulated in prostates of hAR;ETV1
Tg
 mice (FDR ≤ 0.05) and are shown in the heatmap. 
Relative expression in prostates of castrated mice is included. The heatmap is plotted as in Figure 
2.2a, except that each column represents the average expression among biological replicate 
libraries. B) Genes significantly upregulated or downregulated in prostates of hAR;ETV1
Tg
 
relative to hAR mice were uploaded to DAVID for functional annotation with gene ontology 
(GO) terms. The heatmap shows genes annotated with select significantly enriched GO terms 
(Benjamini FDR ≤ 0.05) among the downregulated genes. See Online Resource 2 (Higgins et al., 
2015) for the complete list of significant GO terms. C) The top 1000 upregulated and 
downregulated genes in prostates of hAR;ETV1
Tg
 relative to hAR mice were converted to human 
gene symbols, uploaded to Oncomine as “custom concepts” and queried against the Oncomine 
concept database. Significantly enriched concepts, defined as having an odds ratio (OR) ≥ 4 and 
p ≤ 10-6, are shown as molecular concept maps. Node size is proportional to overlap with the 
primary concept. Similar concepts have the same color and are clustered together. See Online 
Resource 3  (Higgins et al., 2015) for a complete list of significant concepts. 
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Figure 2.4: ETV1 overexpression with Pten reduction promotes progression to 
adenocarcinoma 
 
 H&E stained DLP and VP sections were scored by the pathologist as normal, mPIN2-4 or 
adenocarcinoma (ADC). The graph represents the proportion of mice per group (n = 5-14) at 
each disease stage, with the most severely diseased prostate lobe per mouse used to plot the data.  
See Figure 2.10 for stratification by age and individual prostate lobe. 
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Figure 2.5: Histopathology in Pten-hemizygous mice 
 Representative prostate sections are shown from, in order, intact hAR
12Q
;ETV1
Tg
;Pten
+/-
 
mice with normal, PIN2 or PIN4 DLP, as well as macroscopic DLP tumors (adenocarcinoma) 
from hAR
12Q
;ETV1
Tg
;Pten
+/-
 and hAR
21Q
;ETV1
Tg
;Pten
+/-
 mice. Sections were stained with H&E. 
Immunohistochemical (IHC) staining was performed with antibodies to AR, PTEN or pAKT 
protein (brown staining). In situ hybridization (ISH) was performed with a probe against the 
human ETV1 transcript (red staining). ETV1 expression level is scored as 0-4, with 4 being 
highest. Images are shown at 10x-20x magnification with 60x inset. Consecutive sections were 
used when possible, and each row of images shows stained sections from a single mouse 
prostate. 
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Figure 2.6: Effect of ETV1 on AR targets is muted with reduced Pten 
 A) hAR
12Q
 mice are shown as representative data in all panels. Expression of AR target 
genes Pbsn, Tmprss2, and Nkx3-1 in DLP was measured by qRT-PCR and normalized to Actb. 
Expression levels in intact and castrate hAR
12Q
;ETV1
Tg
, hAR
12Q
;Pten
+/-
 and 
hAR
12Q
;ETV1
Tg
;Pten
+/-
 are plotted relative to intact hAR
12Q
. Lanes 1, 2 and 3 for each gene are 
repeated from Figure 2.2a for comparison between backgrounds. B) Pten expression in DLP was 
measured by qRT-PCR as above. C) hAR expression was measured by qRT-PCR as above. For 
all qRT-PCR, DLP RNA samples were divided into 2 unique pools for analysis. Mean and SEM 
are plotted. The 2
-ddCt
 method was used to calculate relative expression. 
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Figure 2.7: ETV1 overexpression alters genome-wide expression in Pten-hemizygous mice 
 A) Principal component analysis was performed for all genes among the individual RNA-
seq libraries. hAR
12Q
, hAR
21Q
 and hAR
48Q
 mice are represented as triangles, squares and circles, 
respectively. Green and red represent intact non-transgenic and transgenic mice, yellow and blue 
represent castrated non-transgenic and transgenic mice, and orange represents macroscopic 
tumors, respectively. B) RNA-seq analysis was performed on DLP RNA as before. Heatmaps 
include differentially expressed genes between the groups shown (FDR ≤ 0.05), with columns 
representing the average among biological replicate libraries. By GLM analysis of all 
hAR;ETV1
Tg
;Pten
+/-
 libraries vs. all hAR;Pten
+/-
 libraries, 59 genes are upregulated and 3 
downregulated in prostates of hAR;ETV1
Tg
;Pten
+/-
 mice. Select significantly enriched GO terms 
are listed. C) ETV1-upregulated genes shared among Pten
+/-
 and Pten
+/+
 mice are listed. D) 
Differential expression was performed between transgenics and non-transgenics for each AR Q-
tract group individually. Overlap between genes differentially expressed in hAR
12Q
;ETV1
Tg
, 
hAR
21Q
;ETV1
Tg
 or hAR
48Q
;ETV1
Tg
 relative to non-transgenics is illustrated by Venn diagram. 
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Figure 2.8: ETV1-induced inflammatory expression signature precedes tumorigenesis 
 A) Genes that are differentially expressed between hAR;Pten
+/-
 and hAR;ETV1
Tg
;Pten
+/-
 
mice and annotated with inflammation-related GO terms (see Figure 2.7a) are shown in the 
heatmap. Relative expression in prostates of hAR;Pten
+/-
 and hAR;ETV1
Tg
;Pten
+/-
 mice is shown, 
as well as expression in the macroscopic prostate tumors. B) RWPE-1 cells stably expressing AR 
and either ETV1 or LACZ were stimulated with 1 nM R1881 or methanol vehicle, and RNA was 
prepared for qRT-PCR analysis.  Expression of the inflammatory genes CXCL16 and NUPR1 
were normalized to GAPDH or ACTB, respectively, and plotted relative to RWPE-AR-LACZ 
cells.  Mean and SEM are plotted for biological triplicate samples. 
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Figure 2.9: ETV1 effects in mouse DLP parallel those in ETS
+
 and aggressive human PCa 
 A) A set of androgen-induced genes is significantly repressed in hAR;ETV1
Tg
 prostates 
and in Pten
+/-
 tumors. Relative expression across groups is represented in the heatmap. B) Genes 
downregulated in hAR
21Q
;ETV1
Tg
;Pten
+/-
 tumor tissue were uploaded to Oncomine and queried 
against “Oncomine gene expression signatures”. Significant enrichment of genes downregulated 
in human PCa metastases and advanced Gleason grade PCa was observed, and select concepts 
are shown in the molecular concept map. Node size is proportional to the number of genes 
shared with the primary concept. O.R. ≥ 4.0. p ≤ 10-6. C) The heatmap shows the relative 
expression pattern of genes that are significantly downregulated in ETS
+
 vs. non-ETS localized 
tumors from the Taylor Prostate data set as well as in hAR;ETV1
Tg
 mouse prostates or DLP 
tumors. D) The heatmap shows relative expression of genes that are significantly overexpressed 
in ETV1
+
 vs. non-ETS localized tumors from the Grasso Prostate data set as well as in 
hAR;ETV1
Tg
 mouse prostates or DLP tumors. 
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Figure 2.10: Prostate pathology in Pten-hemizygous mice varies with age and lobe 
 A) DLP and VP sections were scored as normal or atrophy (N+A), mPIN2-4 (P2-4) or 
adenocarcinoma (ADC). The median age at sacrifice was 41 weeks, and samples were divided 
into subsets ≤ 41 weeks or > 41 weeks of age. The proportion of samples at each stage was 
plotted per experimental group. Samples were plotted according to the most severely diseased 
lobe. Prostates from 5-14 mice per group were analyzed. B) As in panel A, but DLP and VP 
sections from each mouse were plotted separately for mice of any age. 
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Figure 2.11: Histopathology in Pten-hemizygous mice 
 Additional prostate sections are shown from, in order, an intact hAR
12Q
;Pten
+/-
 DLP, a 
castrated hAR
12Q
;ETV1
Tg
;Pten
+/-
 DLP, an intact hAR
12Q
;Pten
+/-
 VP and a normal region of a 
macroscopic hAR
12Q
;ETV1
Tg
;Pten
+/-
 DLP tumor. Sections were stained with H&E. 
Immunohistochemical (IHC) staining was performed with antibodies to AR, PTEN or pAKT 
protein (brown staining). In situ hybridization (ISH) was performed with a probe against the 
human ETV1 transcript (red staining). ETV1 expression level is scored as 0-4, with 4 being 
highest. Images are shown at 10x-20x magnification with 60x inset. Consecutive sections were 
used when possible, and each row of images shows sections from a single mouse prostate. 
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Figure 2.12: Differential expression by hAR allele in ETV1
Tg
;Pten
+/-
 mice 
 The heatmaps show relative expression of genes differentially expressed (FDR ≤ 0.05) in 
intact ETV1-transgenic vs. non-transgenic mice on the Pten-hemizygous background. Each hAR 
Q-tract allele was analyzed separately. For each group, relative expression in castrated mice is 
included. Each lane represents the average expression from of 2-3 pools of RNA per group. See 
Figure 2.7d for the number of shared and unique genes in each contrast. 
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Chapter 3 
 
Selective antagonism of androgen receptor by ETV1 
in benign and malignant human prostate cells 
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Abstract 
 
 Androgen receptor (AR) signaling, which is central to prostate cancer (PCa) onset and 
progression, cooperates with oncogene activation and tumor suppressor loss to drive 
tumorigenesis. Common somatic alterations include gene fusions that place ETS cell cycle 
transcription factors under AR control, driving elevated expression, or loss of the tumor 
suppressor PTEN. Disruption of either pathway can impact AR activity, but many questions 
remain as to the specific molecular interactions at early vs. late disease stages. 
 It has been suggested that while the ETS factors ETV1 and ERG promote the same 
physiological endpoint, i.e. early neoplasia and invasion, they do so via different molecular 
mechanisms. Chiefly, ERG was thought to repress AR while ETV1 plays a more cooperative 
role. Additional studies suggest that interactions with AR may not be inherently divergent, but 
may depend more on disease stage or the activity of additional signaling pathways such as 
PTEN. 
 In this study, the effect of ETS factors on AR action was explored in benign and 
malignant human prostate cells. In benign RWPE-1 cells, overexpression of either ETV1 or ERG 
repressed androgen induction of luciferase reporters, yet enhanced AR regulation of endogenous 
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chromosomal targets, suggesting that within this cell line ETV1 and ERG have a similar effect 
on AR-regulated gene expression. In malignant PCa cell lines with or without functional PTEN, 
ETV1 knockdown resulted in greater AR activation or repression of target genes, indicating that 
ETV1 was repressing AR action. This included repression of the tumor suppressor gene NKX3-1, 
which was previously noted in ETV1-transgenic mice. Targeted inhibition of PTEN-regulated 
factors (such as AKT) as a proxy for restoring PTEN function in PTEN-null PCa cells did not 
significantly affect the ETV1-AR interaction. ETV1 repression of AR was not achieved through 
differential genomic binding of AR at affected targets, nor was repression associated with altered 
enhancer RNA (eRNA) expression. 
 Together, these results suggest that ETV1 and ERG impact AR signaling in a similar 
direction in multiple experimental systems. ETV1 repression of AR transcriptional activity in 
vitro is highlighted in multiple malignant cell lines, yet appeared to be largely independent of 
PTEN, in contrast to previous in vivo findings. 
 
Introduction 
 
 Multiple aberrant signaling pathways converge to promote PCa progression, with 
different molecular subtypes of prostate tumors harboring disruptions of specific combinations of 
factors (Barbieri et al., 2013; Barbieri and Tomlins, 2014). One of the most common classes of 
somatic alterations in prostate tumors involves genomic rearrangement of oncogenic ETS 
transcription factors early in tumorigenesis. These rearrangements result in fusion of the coding 
region of an ETS gene to androgen-responsive regulatory elements that drive high prostatic 
expression. The ETS factors ERG and ETV1 are rearranged in approximately 50% and 5-10% of 
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tumors, respectively, among PSA-screened Caucasian cohorts (Rubin et al., 2011; Tomlins et al., 
2005). 
 As transgenes or knock-ins in mice, ETV1 and ERG promote prostatic intraepithelial 
neoplasia (PIN) at variable penetrance without progression to adenocarcinoma, confirming a role 
in early neoplasia (Higgins et al., 2015; Shin et al., 2009; Tomlins et al., 2007; Tomlins et al., 
2008a). In combination with Pten deletion, ETV1 and ERG promote more aggressive PIN or 
progression to adenocarcinoma, showing that oncogenic ETS activation can cooperate with 
tumor suppressor loss in PCa (Baena et al., 2013; Carver et al., 2009; Chen et al., 2013; Higgins 
et al., 2015; King et al., 2009). 
 In benign human prostate cells, ETV1 or ERG overexpression increase invasiveness 
without a concomitant increase in proliferation (Baena et al., 2013; Hollenhorst et al., 2011a; 
Tomlins et al., 2007; Tomlins et al., 2008a). ETS rearrangements have been detected in human 
PCa cell lines, including the ERG-positive VCaP line and ETV1-positive LNCaP and MDA-
PCa-2b cells. ERG or ETV1 knockdown in these cells inhibits invasion and anchorage-
independent growth, as well as proliferation in some models, and alters AR transcriptional 
activity (Baena et al., 2013; Chen et al., 2013; Mesquita et al., 2014; Mounir et al., 2014; Shin et 
al., 2009; Tomlins et al., 2007; Tomlins et al., 2008a; Yu et al., 2010). In vitro experiments 
suggest that ERG primarily represses AR by binding near AR binding sites in the genome and 
recruiting the polycomb repressive complex (PRC) to place repressive H3K27me3 marks on 
histones (Baena et al., 2013; Tomlins et al., 2008a; Yu et al., 2010). On the other hand, ETV1 
enhances AR genomic binding and target gene activation in vitro (Baena et al., 2013; Chen et al., 
2013; Shin et al., 2009). 
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 While the interaction between AR and ERG has been studied in several different PCa cell 
lines and consistent AR repression by ERG is observed, experiments focusing on ETV1 and AR 
have primarily been performed in a single cell line (LNCaP) (Baena et al., 2013; Chen et al., 
2013; Shin et al., 2009). It is unclear whether those findings extrapolate to different cellular 
contexts, including whether the PTEN signaling pathway impacts AR-ETV1 interaction. 
Furthermore, little is known about the mechanism by which ETV1 enhances AR genomic 
binding. In previous ETS overexpression experiments in benign cells, AR was absent. Given the 
central role of AR in prostate differentiation and throughout PCa progression, examining ETS 
factors in the context of functional AR is critical. 
 We previously characterized the interaction between genetic variation in AR, 
overexpression of oncogenic ETV1 and reduction of the PTEN tumor suppressor in mice 
(Higgins et al., 2015). ETV1 exhibits a striking antagonism of AR transcriptional activity in the 
context of benign or early neoplastic prostate tissue with normal PTEN levels. With reduced 
PTEN the strong ETV1-AR interaction at the level of AR target gene expression is largely 
abrogated, but there is a general mild reduction in AR activity. Furthermore, the stronger AR 
allele cooperates physiologically with ETV1 overexpression and PTEN reduction to promote 
progression to prostate adenocarcinoma. In macroscopic tumors, AR repression by ETV1 is 
observed as it is in early neoplasia (Higgins et al., 2015). These findings suggest that ETV1 and 
PTEN repression of AR may be important in early as well as later oncogenesis. This is in 
contrast to existing in vitro data primarily showing cooperation between ETV1 and AR (Baena et 
al., 2013; Chen et al., 2013; Shin et al., 2009). These apparent incongruities could be due to in 
vivo vs. in vitro differences, PTEN status, or disease stage of the cells or tissue. To extend the in 
vivo discoveries from the hAR;ETV1
Tg
;Pten
+/-
 mice and elucidate the reasons behind divergent 
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findings, we explored the ETV1-AR interaction in benign and malignant human prostate cell 
lines. 
 Lentiviruses and siRNAs were used to overexpress or knock down AR and ETS factors to 
model direct interaction between these proteins at early, intermediate and late disease stages. AR 
transcriptional regulation of target genes in different cellular contexts was the primary 
experimental endpoint. In benign AR-expressing cells, ETV1 and ERG were studied in parallel 
to determine whether they impact AR signaling in a similar or opposing manner. To test the 
hypothesis that PTEN impacts the ETV1-AR interaction, experiments were performed in 
malignant cell lines with intact vs. absent endogenous PTEN signaling, or following inhibition of 
PTEN-repressed factors as a proxy for restoring PTEN activity. Chromatin immunoprecipitation 
(ChIP) assays were employed to test whether ETV1-driven alterations in AR target gene 
expression are achieved through differential binding of AR or other factors. Together these 
experiments aim to clarify the cellular features influencing the context-dependent interaction of 
ETV1 and AR in human prostate cells. 
 
Results 
 
ETS factors impact AR transactivation in benign prostate cells 
 The effect of ETV1 and ERG on AR transcriptional activity was first tested in 
immortalized benign prostate cells that lack endogenous expression of these factors. Despite 
their origin as normal prostate epithelial cells, in contrast to an early report (Bello et al., 1997), 
RWPE-1 cells do not express of AR (Table 3.1, Figure 3.1). Microsatellite profiling confirmed 
the identity of our RWPE-1 cell line (data not shown). Loss of AR expression is a common 
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phenomenon in cultured benign prostate epithelial cells, also occurring in PrEc cells (Vander 
Griend et al., 2014). 
 RWPE-1 cells were transduced with lentiviral constructs to stably express AR or an FG9 
empty vector control. AR protein in transduced cells was expressed at levels comparable to 
endogenous AR in LNCaP cells (Figure 3.1A), with no AR expression in the empty vector 
control cells (Figure 3.1B). RWPE-AR cells were further transduced with lentiviral constructs to 
stably express truncated ETV1 or ERG, compared with either empty vector or one expressing 
LACZ as a control (Tomlins et al., 2007; Tomlins et al., 2008a). Transduction with ETV1 
lentivirus resulted in 12-fold higher expression, and ERG transduction resulted in a 400-fold 
increase in expression in the absence of hormone (Figure 3.1B). Treatment with the synthetic 
androgen R1881 resulted in a further expression increase (1.4 fold for ETV1, 2-fold for ERG) 
(Figure 3.1B). 
 Interaction of AR and ETS factors was tested first on transfected plasmids as sensitive 
reporter genes. A luciferase reporter driven by a minimal thymidine kinase promoter combined 
with steroid hormone response elements (HRE3-tk-Luc) (Steinkamp et al., 2009) was strongly 
induced by androgen stimulation in the RWPE-AR cells (Figure 3.2A). An additional reporter 
containing approximately 500 bp of the PSA (KLK3) promoter along with 1.3 kb of its enhancer 
cloned from LNCaP cells (PSA-Luc) (Perez-Stable et al., 2000) was also robustly induced in the 
stable RWPE-AR cells (Figure 3.2A). RWPE-FG9 cells showed no luciferase induction 
following androgen treatment, reaffirming the absence of endogenous AR activity (Figure 3.2A). 
Together, these results confirm that while RWPE-1 cells do not express endogenous AR, they 
retain other cellular components necessary to respond to androgen with exogenous AR. 
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 When ETV1 or ERG were stably overexpressed, androgen induction of the HRE3-tk-Luc 
reporter was inhibited by approximately 50%, with greater inhibition of PSA-Luc (Figure 3.2B). 
This result shows that both ETS factors are capable of antagonizing AR transactivation in 
response to androgen. Of note, baseline activity of the PSA-Luc reporter was also reduced 
approximately 50% with ERG or ETV1 overexpression (Figure 3.2B). The PSA sequences 
contain ETS binding sites (Shin et al., 2009) as well as sites for transcription factors in addition 
to AR, suggesting that binding of ETV1 or ERG may inhibit transcription independent of AR. 
These findings are consistent with the striking antagonism of AR by ETV1 seen in normal and 
early neoplastic prostate tissue in the transgenic mice (Figures 2.2A, 2.3A,C) (Higgins et al., 
2015). Furthermore ETV1 and ERG impacted AR activity in the same direction in these 
experiments (Figure 3.2B), whereas they have been reported to have opposite effects on AR in 
malignant PCa cells (Baena et al., 2013; Yu et al., 2010). 
 We next examined how ETV1 or ERG overexpression impacted AR transcriptional 
activity at endogenous target genes. A number of canonical AR target genes are not androgen-
regulated in RWPE-AR cells, including TMPRSS2 and KLK3 (data not shown). However, 
exogenous AR regulates a broader set of targets in these cells (Altintas et al., 2011). In RWPE-
AR-LACZ control cells, stimulation with 1 or 10 nM R1881 resulted in induction of AQP3 and 
MME expression, as well as repression of NT5E (Figure 3.3). Stable overexpression of ETV1 or 
ERG enhanced activation or repression of these AR targets (Figure 3.3). Intriguingly, these 
effects were seen in the absence of hormone and were greater with 1 nM R1881. This suggests 
that ETV1 and ERG may influence the activity of the basal transcriptional machinery or other 
transcription factors independent of AR. As with the luciferase reporters, ETV1 and ERG act in 
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the same direction on the endogenous targets with regard to their effect on androgen signaling, 
although in this case it is accentuating rather than countering AR action. 
 
ETV1 antagonizes AR in metastatic PCa cell lines 
 The ETV1-AR interaction was next probed in two cell lines, MDA-PCa-2b and LNCaP, 
derived from human PCa metastases (Table 3.1). Both lines overexpress ETV1 due to genomic 
rearrangements, and both express AR, allowing study of the endogenous factors. MDA-PCa-2b 
cells retain PTEN expression and represent an earlier disease stage, while LNCaP cells have lost 
PTEN and represent a later, though still androgen-dependent, phase. siRNA was used to knock 
down ETV1 and the impact on AR transcriptional activity tested. 
 Transfection of siRNA targeting ETV1 (siETV1) in MDA-PCa-2b cells resulted in 
approximately 60% ETV1 knockdown relative to non-targeted siRNA (siScr) (Figure 3.4). 
MDA-PCa-2b cells express high levels of ETV1and this level of knockdown was not increased 
up to 25 nM siETV1 (data not shown), suggesting that the 60% knockdown of ETV1 was also 
the maximum achievable with a short hairpin RNA (shRNA) in these cells (Mesquita et al., 
2014). shRNA data suggest that total knockdown can be lethal, at least in the case of ERG (Scott 
Tomlins, personal communication). 
 Following siETV1 transfection, treatment of MDA-PCa-2b cells with 10nM R1881 
induced up to a 7-fold increase in expression of the AR targets tested (Figure 3.4). FKBP5, 
NKX3-1 and AQP3 expression levels increased above androgen-induced levels with ETV1 
knockdown. KLK3 showed a trend toward decreased expression, while TMPRSS2 and MME 
were unaffected (Figure 3.4). MME, which is strongly androgen-induced in RWPE-AR cells, is 
modestly androgen-repressed in MDA-PCa-2b. siETV1 altered expression of AQP3 and NKX3-1 
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in the absence of androgen as well, suggesting that ETV1 is capable of interacting with the basal 
transcriptional machinery or other factors. While not all AR target genes queried showed a 
significant effect of ETV1 knockdown, those that did suggested that ETV1 was inhibiting AR 
transcriptional activity. Importantly, the ETV1-repressed genes include the tumor suppressor 
NKX3-1, which was also inhibited in pre-neoplastic prostates and tumors of ETV1
Tg
 mice 
(Figures 2.2A, 2.3B, 2.9A) (Higgins et al., 2015). 
 LNCaP cells were used to test the ETV1-AR interaction in the context of PTEN loss. 
Transfection with siETV1 reduced expression by approximately 80% at the transcript level 
relative to cells transfected with siScr or to untransfected cells (Figure 3.5A). Effective 
knockdown persisted for at least 48-96 hours post-transfection (data not shown). A reduction in 
ETV1 protein was verified by Western blot (Figure 3.5A, compare left 4 bands to right 4 bands), 
but due to the high level of background with the ETV1 antibody, qRT-PCR was more routinely 
used to gauge knockdown. Following ETV1 knockdown, cells were stimulated with 1 nM or 10 
nM DHT to replicate the experimental conditions of a recent report as closely as possible (Baena 
et al., 2013). 
 ETV1 knockdown significantly enhanced AR activation of the target genes KLK3, NKX3-
1 and TMPRSS2 following androgen stimulation, with a trend toward increased FKBP5 
expression (Figure 3.5B). MME is not normally androgen-induced in LNCaP cells, but siETV1 
significantly increased MME expression with 10 nM DHT. ETV1 knockdown enhanced AR-
mediated repression of AQP3 (Figure 3.5B). These results implied that endogenous ETV1 
antagonizes AR activation as well as repression of target genes in LNCaP cells. This finding was 
consistently obtained for multiple experimental conditions, despite reports of ETV1-AR 
cooperation in LNCaP cells (Baena et al., 2013; Chen et al., 2013; Shin et al., 2009) (see 
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discussion). ETV1 knockdown similarly affected basal transcription of TMPRSS2, NKX3-1 and 
AQP3, again suggesting the influence of other factors. 
 
Interaction between ETV1 and PI3K/AKT pathways 
 Given the striking antagonism of AR by ETV1 and the loss of that antagonism with 
reduced PTEN in mice (Higgins et al., 2015), we hypothesized that PTEN signaling could act, in 
some contexts, as a "switch" that influenced  ETV1-AR interaction. Despite the unexpectedly 
similar results in MDA-PCa-2b (PTEN
+
) and LNCaP (PTEN
-
) cells, the ETV1-AR interaction 
was further probed to determine whether altered PTEN activity exerted an influence within this 
cell line. As a proxy for restoring PTEN signaling in the PTEN-null LNCaP cells, AKT and 
PI3K signaling were inhibited, either with AKT siRNA (siAKT) or with the dual PI3K/mTOR 
inhibitor NVP-BEZ235 (BEZ235) (Serra et al., 2008). 
 Treatment with siAKT led to almost complete loss of total AKT protein, but levels of 
phospho-AKT (pAKT), the active form of the protein, were reduced only 2-4 fold (Figure 3.6A). 
This suggests that pAKT is more stable than the un-phosphorylated protein, or that there is high 
kinase or low phosphatase activity targeting AKT. 
 Treatment with either siAKT or siETV1 resulted in a trend toward increased androgen-
stimulated expression of the AR target genes TMPRSS2 and FKBP5 (Figure 3.6B). This is 
consistent with reports describing inhibition of AR activity by the PI3K/AKT pathway (Carver et 
al., 2011; Mulholland et al., 2011). Simultaneous knockdown of both ETV1 and AKT trended 
toward an additive increase in androgen-stimulated expression of FKBP5, while TMPRSS2 
expression was no greater than with siETV1 alone (Figure 3.6B). Intriguingly, siAKT increased 
expression of the androgen-repressed gene AQP3 while siETV1 trended toward reduced 
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expression even in combination with siAKT. This result shows that AKT inhibition may affect 
AR-mediated activation and repression differently. Furthermore, at these targets AKT and ETV1 
appear to act independently, with a trend to additivity in some cases. While variance was large 
and effect sizes small, this experiment did not provide evidence that AKT signaling is a switch 
controlling the effect of ETV1 on AR target gene regulation. 
 Treatment with 500 nM BEZ235 reduced pAKT protein without affecting total AKT 
(Figure 3.6C), confirming that the target of BEZ235 is PI3K, which results in reduced AKT 
activity but not expression. 500 nM BEZ235 significantly increased androgen-induced 
expression of TMPRSS2 and caused a non-significant increase in FKBP5 levels (Figure 3.6D). 
These results are again consistent with recent reports describing PI3K/AKT inhibition of AR 
(Carver et al., 2011; Mulholland et al., 2011) and with the effect of AKT knockdown by siRNA 
(Figure 3.6B). When BEZ235 and siETV1 were combined, androgen-induced expression of both 
TMPRSS2 and FKBP5 were greater than with siETV1 alone. For FKBP5 there was a trend 
toward an additive increase in expression. Concurrent ETV1 knockdown slightly reduced the 
BEZ235-induced increase in TMPRSS2 expression with DHT, but not below that seen with only 
siETV1. Thus neither target revealed combinatorial action of ETV1 and P13K, dampening the 
notion that PI3K signaling acts as a switch to control the ETV1-AR interaction, at least in 
LNCaP cells. 
 
AR genomic binding is not perturbed by ETV1 in metastatic PCa cells 
 ETS binding sites frequently reside near AR binding sites in the genome, and ERG is 
known to repress AR binding in vitro (Yu et al., 2010). Therefore, we hypothesized that ETV1 
might antagonize AR transcriptional activity by disrupting AR binding at target genes. 
91 
 
Chromatin immunoprecipitation (ChIP) was performed following ETV1 knockdown in LNCaP 
cells. Target sequences for qPCR were selected based on overlapping AR and ETV1 binding 
sites observed in ChIP-seq studies. Priority was given to sites where AR binding is enhanced by 
androgen stimulation as well as by ETV1, such as the TMPRSS2 -13 kb enhancer (Figure 3.7A) 
(Baena et al., 2013; Chen et al., 2013; Yu et al., 2010).  
Cells were transfected with siETV1 or siScr and treated for 4 hours with 10 nM DHT or 2 
hours with 1 nM R1881 before harvesting chromatin. Genomic binding of AR or RNA PolII 
(PolII) was detected with specific antibodies vs. IgG-only control, and enrichment at target 
sequences was quantified by qPCR. In an initial experiment, DHT stimulation successfully 
increased binding of AR and PolII at the TMPRSS2 and PSA (KLK3) enhancers relative to 
methanol-treated cells (Figure 3.7B). Since the synthetic androgen R1881 has a higher binding 
affinity for AR and is not metabolized in the cell, R1881 was used subsequently.  
LNCaP cells were transfected with siETV1 or siScr and treated with 1 nM R1881 or 
vehicle. Enrichment above the IgG control was observed for AR and RNA PolII binding at the 
TMPRSS2 -13kb enhancer with 1 nM R1881. However, ETV1 knockdown did not significantly 
affect AR or PolII binding at the TMPRSS2 enhancer (Figure 3.7C) or promoter (data not shown) 
despite having the expected effect on TMPRSS2 gene expression (Figure 3.7D). As a control, 
PolII bound to the GAPDH transcription start site (TSS) while AR signal was at background 
levels (Figure 3.7C). Unfortunately, ETV1 binding could not be detected above IgG background 
in any experimental run, probably due to the poor quality of the commercial antibody. In 
summary, there was no evidence for an impact of ETV1 on AR or PolII binding at the TMPRSS2 
promoter or enhancer. 
92 
 
 An alternative hypothesis to explain how ETV1 inhibits expression of TMPRSS2 and 
other AR target genes is altered enhancer RNA (eRNA) expression, rather than a direct effect on 
AR binding. Next-generation sequencing applications such as global run-on sequencing (GRO-
seq) (Core et al., 2008) and bromouridine sequencing (Bru-seq) (Paulsen et al., 2014) allow 
nascent RNA to be purified and sequenced. Such experiments have revealed that enhancers are 
actively transcribed, rather than simply serving as a docking site for transcription factors from 
which to act on distal targets. TMPRSS2 eRNA transcription was recently characterized (Puc et 
al., 2015), and the primer sequences from that report were used to test for differential TMPRSS2 
eRNA expression following ETV1 knockdown in LNCaP cells. While R1881 stimulation 
increased eRNA expression, siETV1 had no significant effect on expression at either the basal 
level or following androgen treatment (Figure 3.7). The inhibition of TMPRSS2 expression by 
ETV1 does not appear to be mediated by altered eRNA expression. 
 
Discussion 
 
 The aim of these experiments was to study direct interactions between ETV1 and AR in 
human prostate cells representing progressive disease stages, with a focus on confirming and 
extending observations made in the ETV1
Tg
 mice (Higgins et al., 2015). Collectively, the data 
reveal that ETV1 has the capacity to enhance or repress AR signaling depending on cellular 
context. AR activation of luciferase reporters is antagonized by both ETV1 and ERG in benign 
cells, yet at endogenous genes both activation and repression by AR are enhanced. In two 
metastatic PCa cell lines, ETV1 represses AR induction of target genes regardless of PTEN 
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status. This repression does not appear to be mediated through altered AR or PolII binding at the 
gene promoter or enhancer. 
 It was initially surprising to observe such repression in LNCaP cells, as cooperation 
between ETV1 and AR had previously been reported in that cell line (Baena et al., 2013; Shin et 
al., 2009). Despite mirroring experimental conditions as closely as possible, including the same 
siETV1 reagent and qRT-PCR primer sequences, those results could not be replicated. To verify 
that the LNCaP cells retained their critical features, the AR gene was sequenced and the presence 
of the T877A mutation confirmed. Additionally, Western blot analysis showed that the LNCaP 
cells lacked PTEN protein expression and had high pAKT expression, as expected. The cells 
robustly expressed ETV1 that could be knocked down with targeted siRNA. The effect was not 
due to differential expression of the housekeeping gene used to normalize expression levels, as 
ACTB was not significantly affected by ETV1 knockdown. The experiment was repeated with 
fresh LNCaP cells ordered directly from ATCC, and similar results were obtained. Cells were 
negative for Mycoplasma by PCR assay. In our hands, ETV1 consistently antagonized AR in 
LNCaP cells. 
 It is possible that some technical factor such as serum brand or culture condition had an 
influence over time. Expression of different ETS factors within the same cell line varies between 
labs (Hollenhorst et al., 2011b; Mesquita et al., 2014; Pellecchia et al., 2012). Subtler variation in 
expression level of AR, ETV1 and other factors among sublines is also possible. Nevertheless, in 
our hands ETV1 appears to be a repressor of AR both in vivo (Higgins et al., 2015) and in 
malignant prostate cells, similar to findings with ERG (Baena et al., 2013; Tomlins et al., 2008a; 
Yu et al., 2010). 
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 While previous reports have studied ETS factors in the benign RWPE-1 cell line, this 
work is the first to look at the interaction between stably expressed ETV1 or ERG together with 
AR. Of note, ETV1 and ERG affect AR signaling in the same "direction" for a given target. Both 
factors inhibit androgen induction of luciferase reporters, yet enhance the induction or repression 
of androgen-induced or -repressed genes, respectively. For some targets these effects are seen 
even in the absence of hormone, suggesting that ETV1 and ERG can interact with the basal 
transcriptional machinery. AQP3 and MME have known roles in oncogenesis. AQP3, a water 
and small solute channel, promotes motility and invasion of PCa cells, in part through increased 
MMP3 expression and ERK signaling (Chen et al., 2015). MME, also known as CD10, NEP or 
neprilysin, is an endopeptidase associated with poor prognosis in esophageal squamous cell 
carcinoma and other cancers (Lee et al., 2015). MME was previously shown to exert tumor 
suppressive functions in PCa cell lines, mediated in part by facilitating inhibition of PI3K by 
PTEN (Sumitomo et al., 2005). On average, MME levels are reduced in both localized and 
metastatic tumors relative to normal tissue in PCa patients. However, increased MME in either 
localized or metastatic PCa is associated with poor survival (Fleischmann et al., 2011). Both 
AQP3 and MME are expressed in normal tissues, and perhaps their inappropriate activation by 
ETV1 or ERG could contribute to early disease. 
 ETV1 and ERG promote similar physiological outcomes, e.g. invasion in vitro and early 
neoplasia in vivo, but it has been suggested that they do so through divergent gene expression 
programs (Baena et al., 2013). The emerging picture from our work and other recent studies is 
that ETV1 and ERG may be more similar than different. It may largely be the cellular context 
that influences their differential activity rather than inherently divergent function (Chen et al., 
2013). 
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 In vitro, PTEN status does not appear to be a "switch" that controls the effect of ETV1 on 
AR action. In both MDA-PCa-2b and LNCaP cells (PTEN-positive and -negative, respectively) 
ETV1 antagonizes AR regulation of target genes, though the specific subset of affected targets 
varies slightly between lines. Inhibiting PI3K/pAKT signaling, in effect partially restoring PTEN 
function, did not significantly alter ETV1-AR antagonism in LNCaP cells. Broader differences in 
the transition from benign to malignant cells may be important, as AR regulation of endogenous 
targets was enhanced by both ETV1 and ERG in benign RWPE-1 cells. It remains to be seen 
whether PTEN knockdown in benign prostate cells or in malignant MDA-PCa-2b cells affects 
the ETV1-AR interaction. 
 In the AKT knockdown experiments, pAKT appeared to be more stable than the un-
phosphorylated protein (Figure 3.6). This is perhaps surprising, as AKT phosphorylation at 
Ser473 has been reported to promote polyubiquitination and proteasomal degradation (Wu et al., 
2011). However, those experiments were carried out in 293T or MEF cells with tagged, 
overexpressed AKT. Other groups report that dephosphorylating AKT at Ser473 does not alter 
stability (Liao and Hung, 2010). It is possible that the ubiquitin ligase, kinase or phosphatase that 
target AKT are present at different levels in LNCaP cells under the current experimental 
conditions. 
 Recent evidence suggests that eRNA transcription at enhancers plays an active role in 
promoting transcription of the target gene, in part through stabilization of chromatin looping (Li 
et al., 2013). Such eRNAs have been reported to be involved in estrogen receptor (ER) and AR-
mediated transcription (Li et al., 2013; Puc et al., 2015). eRNA inhibition could affect expression 
of the neighboring gene, but in LNCaP cells ETV1 repression of TMPRSS2 expression does not 
appear to be due to differential expression of the TMPRSS2 eRNA. The TMPRSS2 antagonism 
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by ETV1 is not due to differential binding of AR or RNA PolII upstream of TMPRSS2 either. It 
remains possible that ETV1 inhibits active transcription by PolII, causing it to remain "poised" at 
the promoter or enhancer. ChIP for histone modifications marking active transcription such as 
H3K36me3 (Hon et al., 2009) could address this hypothesis, as could testing for PolII binding 
further downstream in the TMPRSS2 gene body. 
 In these experiments, both ETV1 and ERG affected expression of a number of target 
genes even in the absence of androgen. In PCa cells, ERG is known to recruit the polycomb 
repressive complex (PRC) to AR target genes, resulting in placement of H3K27me3 marks and 
transcriptional repression (Yu et al., 2010). ChIP for PRC components or H3K27me3 histone 
modifications would test the hypothesis that ETV1 utilizes a repressive mechanism similar to 
ERG, in effect acting as an "anti-pioneer" factor. 
 Thus far it has been presumed that ETV1 antagonizes AR primarily at the level of target 
gene transcription, as both proteins are transcription factors and are known to have overlapping 
binding sites. Because standard qRT-PCR and even RNA-seq represents a static "snapshot" of 
transcript levels, it remains possible that ETV1 affects post-transcriptional mRNA stability rather 
than transcription. Alternatively, the rate of extension could be slowed despite a similar rate of 
transcription factor binding and initiation. Bru-seq following ETV1 knockdown and androgen 
stimulation would clarify whether differential expression of TMPRSS2 and other AR targets is 
transcriptionally mediated, as Bru-seq enriches for nascent RNA. As a more general experiment, 
Bru-seq combined with ChIP-seq in androgen-stimulated prostate cells would clarify which 
androgen-induced or -repressed genes are primary AR and ETV1 targets and which genes are 
induced (or repressed) secondarily. 
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 Overall, these experiments highlight the capacity for ETV1 to selectively repress AR 
signaling in benign and malignant human prostate cells, with or without PTEN signaling. 
Consistent ETV1 inhibition of the androgen-induced tumor suppressor NKX3-1 in multiple PCa 
cell lines as well as in mice (Higgins et al., 2015) supports a model in which ETV1 acts by 
disrupting the pro-differentiation expression program normally regulated by AR. At both early 
and later disease stages this push toward dedifferentiation may prime prostate cells for 
transformation following additional oncogenic events. 
 
Materials and Methods 
 
Cell lines 
 RWPE-1 cells (ATCC cat. # CRL-11609), as well as stably transduced RWPE-AR, 
RWPE-ETS and RWPE-AR-ETS cells, were maintained in KSFM (Gibco) with EGF and BPE 
supplements (included) plus 1:100 penicillin/streptomycin (Gibco). LNCaP cells (ATCC # CRL-
1740) were maintained in RPMI1640 (Gibco) with 10% FBS (GeneMate) and 1:100 
penicillin/streptomycin. MDA-PCa-2b cells (ATCC # CRL-2422) (a gift from Dr. Arul 
Chinnaiyan) were maintained in F12K medium (Gibco) with 20% FBS, 5 ng/ml insulin, 10 
ng/ml EGF, 25 ng/ml cholera toxin, 100 pg/ml hydrocortisone and 1:100 penicillin/streptomycin. 
 To maintain stable expression of AR or FG9 empty vector control constructs, 100 μg/ml 
Hygromycin B (Invitrogen) was added to the complete growth medium. To maintain stable 
expression of ETV1, ERG, LACZ or pLenti empty vector control constructs, 3 μg/ml 
Blasticidin-HCl (Invitrogen) was added to the complete growth medium. 
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RWPE-ETS-AR transduction 
 For details regarding cloning of the FG9-3xFLAG-AR plasmid and its stable transduction 
into RWPE-ETS cells, see Chapter 2. In order to generate comparable RWPE cells stably 
expressing AR without the 3xFLAG tag, an AR fragment was first excised from the 
p5HBhARcDNA plasmid (gift from Dr. Andrew Lieberman) with BamHI and BglII restriction 
enzymes. The FG9 lentiviral plasmid was then linearized with BamHI, and the 3.1kb AR 
fragment was ligated to linearized FG9 to generate FG9-AR. The ligation product was 
transformed into One-Shot Stbl3 competent cells (Invitrogen) and colony PCR was performed 
with primers flanking each ligation site to check orientation. FG9-AR was packaged into a 
lentivirus and transduced into RWPE cells as in Chapter 2. 
 
Western Blot 
 The primary antibodies and dilutions used for Western blots include AR (Santa Cruz # 
sc-816, 1:500), GAPDH (Millipore # MAB374, 1:10000), ETV1 (Abcam # 81086, 1:500), AKT 
(Cell Signaling # 9272, 1:1000), pAKT (Cell Signaling # 9271, 1:1000) and β-tubulin (Santa 
Cruz # sc-9104, 1:1000). The secondary antibody was HRP-conjugated anti-rabbit IgG (Santa 
Cruz # sc-2313, 1:5000). HRP signal was detected with ECL Western Blotting Substrate (Pierce) 
according to the manufacturer's instructions. 
 
RWPE-AR-ETS Luciferase transfection and androgen stimulation 
 50,000 cells per well were seeded into 12-well plates in complete growth medium. In all 
in vitro experiments, cells were counted and seeded from independently maintained flasks, as 
well as transfected and hormone-stimulated from independently prepared solutions, in order to 
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obtain biological replicates. The following day, medium was changed to KSFM with only EGF 
supplement for 4 hours. Cells were then transfected with 400 ng Firefly luciferase reporter 
plasmid, 25 ng pHRL-null Renilla luciferase control plasmid and 1.275 μl ("3:1" ratio) 
XTremeGene9 transfection reagent (Roche) in 50 μl OPTI-MEM (Gibco). Luciferase reporters 
include PSA-Luc (Perez-Stable et al., 2000) and 3xHRE3-Luc (Steinkamp et al., 2009). The 
following day, cells were stimulated with 1-10 nM R1881 or methanol vehicle for 24 hours. 
Cells were gently shaken for 30 minutes in 250 μl 1x passive lysis buffer (Promega), and 10 μl 
per well was read on a Turner Biosystems Veritas Luminometer using Dual-Luciferase Reporter 
Assay reagents (Promega). Luciferase activity per sample was expressed as the ratio of Firefly 
luciferase counts (reporter) to Renilla .luciferase counts (control) in each well. Mean and SEM 
were plotted. 
 
RWPE-ETS-AR androgen stimulation and endogenous gene expression 
 50,000 cells per well were seeded into 12-well plates in complete growth medium. The 
following day, medium was changed to KSFM with EGF supplement only for 48 hours. Cells 
were then stimulated with 1-10 nM R1881 or methanol vehicle for 24 hours. RNA was harvested 
by lysing the cells in TRIzol reagent (Invitrogen) and purifying RNA according to the standard 
TRIzol protocol. 
 
siRNA knockdown of ETV1 followed by androgen stimulation 
 10 cm dishes (for chromatin) or 6-well plates (for RNA) were pre-coated with poly-L-
lysine (Sigma) to enhance cell adherence. LNCaP cells were counted on a hemacytometer and 
250,000 cells were seeded per well, or scaled up to 1,375,000 cells per 10 cm dish. After 48 
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hours the cells were transfected with 5 nM ETV1 siRNA (ETV1 ON-TARGET siRNA 
SmartPool, Dharmacon # L-003801-00-0005) or non-targeting siRNA (Non-Targeting Control 
siRNA #1, Dharmacon # D-001801-01-05) suspended in OPTI-MEM with DharmaFect 3 
transfection reagent (Dharmacon # T-2003-03) according to the manufacturer’s protocol. 24 
hours later, medium was changed to RPMI 1640 with 10% charcoal-stripped Nu-Serum 
(Corning) to starve cells of hormones for 48 hours. Cells were then treated with 1 nM or 10 nM 
DHT for 4 hours or 1nM R1881 for 2 hours (for chromatin) or 16 hours (for RNA). Chromatin 
was harvested as described above. RNA was harvested by lysing the cells in TRIzol reagent 
(Invitrogen) and purifying RNA according to the standard TRIzol protocol. 
 For MDA-PCa-2b cells the protocol for siRNA transfection and androgen stimulation 
was essentially identical to that described above for LNCaP. However, cells were starved for 
only 24 hours in F12K medium containing 10% CSNS and all supplements except 
hydrocortisone. 
  
PI3K pathway inhibition 
 The PI3K/mTOR inhibitor NVP-BEZ235 was obtained from Cayman Chemical 
Company (# 10565). LNCaP cells were seeded and transfected with siETV1 as described above. 
During DHT stimulation, cells were co-treated with 500 nM BEZ235 or DMSO vehicle and 
harvested the following day as described above. 
 AKT siRNA (siAKT) (Cell Signaling # 6211) was used to knock down AKT in vitro. 
LNCaP cells were seeded and hormone-stimulated as described above, and 5 nM siAKT was co-
transfected with siETV1 or siScr. 
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Chromatin immunoprecipitation (ChIP) 
 To crosslink DNA and proteins, formaldehyde was added directly to the cell culture 
medium to a concentration of 2% and dishes were gently shaken 30 minutes at room 
temperature. Crosslinking was stopped by the addition of glycine to a final concentration of 
0.125 M and 5 minutes of additional shaking. Cells were rinsed twice with cold PBS, then 
scraped and collected twice in 3 ml cold PBS. Cells were pelleted for 4 minutes at 2,000 rpm at 
4°C in a benchtop centrifuge. Pellets were resuspended in 400 ul hypotonic buffer (25 mM 
HEPES, 5 mM KCl, 0.5 mM MgCl2, 1 mM DTT, 0.5% NP-40) with 1x Halt Protease Inhibitor 
cocktail (Pierce), rotated 15 minutes at 4°C and pelleted for 1 minute at 2,500 rpm at 4°C. 
Pelleted nuclei were resuspended in 400 μl SDS lysis buffer (1% SDS, 10 mM EDTA pH 8.0, 50 
mM Tris-Cl pH 8.0) with 1x protease inhibitors and incubated on ice ≥ 10 minutes. Chromatin 
was sheared to 200-1,000 bp by sonication on a Branson Sonifier Cell Disruptor 185. Each 
sonication cycle consisted of a 10 second sonication pulse at power setting 5, followed by at least 
60 seconds on ice. LNCaP cells were sonicated for 8 cycles. Cell debris was pelleted for 10 
minutes at maximum speed in a microcentrifuge at 4°C and discarded. The concentration of 
chromatin was determined on a NanoDrop spectrophotometer. 
 Protein A agarose beads (Invitrogen) were washed twice in RIPA buffer and resuspended 
in RIPA buffer with 1x protease inhibitors, along with 37.5 ng/μl salmon sperm DNA and 50 
ng/μl BSA to block non-specific binding of DNA and proteins. For each IP, 10-25 μg chromatin 
was first diluted into 500 μl RIPA buffer with 1x protease inhibitors. Chromatin was pre-cleared 
by adding 60 μl washed/blocked protein A agarose beads and rotating 1 hour at 4°C. Beads were 
pelleted by spinning 2 minutes at maximum speed at 4°C and discarded, and cleared chromatin 
was transferred to a new tube. 2-5 μg antibody was added to each tube, and tubes were rotated 
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overnight at 4°C. For each sample, an "Input" tube was pre-cleared and rotated overnight with no 
antibody added. The antibodies used for ChIP include: AR (Abcam # ab74272, 5 μg), AR (Santa 
Cruz # sc-816, 5 μg), RNA PolII (Active Motif # 39097, 2 μg), ETV1 (Abcam # 81086, 2 μg) 
and IgG control (Santa Cruz # sc-2027, 2 μg). 
 Antibody/chromatin complexes were precipitated by adding 30 μl washed/blocked 
protein A agarose beads to each tube (except Inputs) and rotating overnight at 4°C. Beads were 
pelleted 2 minutes at 3,000 RPM at 4°C and the supernatant was discarded. The beads were 
washed with 1 ml each of: low salt immune complex wash buffer (0.1% SDS, 1% Triton X-100, 
2 mM EDTA, 20 mM Tris-HCl pH 8.0, 150 mM NaCl), high salt immune complex wash buffer 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 500 mM NaCl), LiCl 
immune complex wash buffer (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM 
Tris-HCl pH 8.0), and twice with TE buffer, rotating for 5 minutes at 4°C for each wash. After 
each wash, beads were pelleted as above and the supernatant discarded. Chromatin was then 
eluted from the beads twice by rotating 15 minutes in 250 μl ChIP elution buffer (1% SDS, 0.1 
M NaHCO3, freshly mixed). In each elution beads were pelleted as above and eluates combined 
in a new tube. NaCl was added to the eluates to a concentration of 0.2 M and samples were 
incubated between 4 hours and overnight to reverse crosslinks. 20 μg proteinase K, EDTA pH 
8.0 to 10 mM and Tris-HCl pH 6.5 to 20 mM were added, and the samples were incubated 1 
hour at 45°C. ChIP DNA was then purified with a QiaQuick PCR Purification Kit (Qiagen). 2-4 
μl ChIP DNA was used per qPCR reaction. 
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cDNA reverse transcription 
 RNA was quantified on a NanoDrop or Pharmacia Biotech GeneQuant II 
spectrophotometer, and 1 μg total RNA was used as input for the reverse-transcription reaction. 
If any samples were too dilute to reach 1 μg within the standard reaction volume, input RNA for 
all samples in the experiment was scaled down to the maximum allowed by the most dilute 
sample. cDNA was synthesized with the High Capacity cDNA Reverse Transcription kit with 
RNase inhibitor (Applied Biosystems) according to the manufacturer's recommendations. cDNA 
products were diluted 1:20, and 2 μl diluted cDNA was used per subsequent PCR well. 
 
Quantitative PCR 
 Quantitative PCR (qPCR) was performed on an AB7500 thermal cycler (Applied 
Biosystems) using ABsolute Blue qPCR SYBR Green Rox mix (Thermo Scientific) according to 
the manufacturer's instructions, with reactions scaled down to 20 μl. The optional melt curve was 
used to ensure a single, consistent melting temperature (Tm) among all samples for each primer 
pair. Samples with low Tm (indicating predominantly primer-primer PCR products), or samples 
with multiple or divergent Tm (indicating non-specific amplification) were repeated. 
 Relative gene expression was calculated using the 2
-ddCt
 method. Briefly, dCt was 
obtained by normalizing each biological sample's threshold cycle (Ct) value for each gene of 
interest to a housekeeping gene that was amplified on the same plate (ACTB or GAPDH). Then 
ddCt values were obtained by normalizing to the reference sample or group dCt. The 2
-ddCt
 
transformation gave expression of each sample relative to the reference. Mean expression and 
standard error (SEM) were then calculated and plotted for experimental replicates. 
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 ChIP enrichment was calculated as "% Input" in a manner analogous to the 2
-ddCt
 method 
used for expression. However, for each sample and target sequence, the Ct value for each 
antibody was first subtracted from the Ct of the Input for that sample. The "2
dCt
" transformation 
gave enrichment of each antibody relative to the Input, and this value was converted to a 
percentage to plot as "% input". As with expression, mean and SEM were calculated for 
experimental replicates. All primer sequences are listed in Table 3.2.  
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Table 3.1: Human prostate cell line characteristics 
     
     Cell Line Source AR PTEN ETS  
RWPE-1  
normal prostate 
epithelium 
(immortalized) 
null + 
moderate ETV1 expression 
(fusion-negative) 
MDA-
PCa-2b  
PCa (bone metastasis) L701H;T877A  +  
ETV1 overexpression 
(gene fusion)  
LNCaP 
PCa (lymph node 
metastasis)  
T877A  - 
ETV1 overexpression 
(locus insertion)  
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Table 3.2: Real-time PCR primer sequences 
(all sequences 5'-3') 
 
  qRT-PCR 
 ACTB F CAAAGACCTGTACGCCAACA 
ACTB R TCAGGAGGAGCAATGATC 
AQP3 F TTGGCTTTGCTGTCACTCTG 
AQP3 R GTAGATGGGCAGCTTGATCC 
AR F CAGTGGATGGGCTGAAAAAT 
AR R GGAGCTTGGTGAGCTGGTAG 
ERG F CGCAGAGTTATCGTGCCAGCAGAT 
ERG R CCATATTCTTTCACCGCCCACTCC 
ETV1 F CTACCCCATGGACCACAGATTT 
ETV1 R CTTAAAGCCTTGTGGTGGGAAG 
FKBP5 F CGCAGGATATACGCCAACAT 
FKBP5 R CTTGCCCATTGCTTTATTGG 
GAPDH F TGCACCACCAACTGCTTAGC 
GAPDH R GGCATGGACTGTGGTCATGAG 
KLK3 F CACCTGCTCGGGTGATTCTG 
KLK3 R CCACTTCCGGTAATGCACCA 
MME F CCGAACCTACAAGGAGTCCA 
MME R GCAAATGCTGCTTCCACATA 
NKX3-1 F GAGACGCTGGCAGAGACC 
NKX3-1 R CGCCTGAAGTGTTTTCAGAG 
NT5E F CTGGGAGCTTACGATTTTGC 
NT5E R GCTGAACCTTGGTGAAGAGC 
TMPRSS2 (eRNA) F GAAAGGAATGGGGGTTTGAGG 
TMPRSS2 (eRNA) R TGCCTGGAAGACGTGGTTTTT 
TMPRSS2 (mRNA) F TACTCTGGAAGTTCATGGGC 
TMPRSS2 (mRNA) R GTCATCCACTATTCCTTGGCT 
  ChIP 
 KLK3 (enhancer) F GCCTGGATCTGAGAGAGATATCATC 
KLK3 (enhancer) R ACACCTTTTTTTTTCTGGATTGTTG 
TMPRSS2 (enhancer) F TGGAGCTAGTGCTGCATGTC 
TMPRSS2 (enhancer) R CTGCCTTGCTGTGTGAAAAA 
GAPDH (TSS) F TACTAGCGGTTTTACGGGCG 
GAPDH (TSS) R TCGAACAGGAGGAGCAGAGAGCGA 
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Figure 3.1: Stable AR, ETV1 and ERG expression in RWPE-1 cells
Benign RWPE-1 prostate cells were transduced with lentiviral constructs to stably express AR 
or empty vector, and then with additional lentiviral vectors to stably express ETV1, ERG or empty vector. A) 
A Western blot shows AR protein levels in stable RWPE-AR cells compared to endogenous AR in LNCaP 
cells. B) qRT-PCR shows robust, specific expression of AR, ETV1 or ERG, with no expression in the empty 
vector-transduced controls. Expression was normalized to ACTB, with mean and SEM plotted for biological 
triplicate samples. Grey bars represent androgen-induced expression and white bars represent vehicle 
control.
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Figure 3.1: Stable AR, ETV1 and ERG expression in RWPE-1 cells 
 
 Benign RWPE-1 prostate cells were transduced with l ntiviral constructs to stably 
express AR, r with empty vector (FG9), and then with addition l lentiviral vectors expressing 
ETV1, ERG or empty vector. A) A W stern blot shows AR protein levels in stable RWPE-AR 
cells compared to e d genous AR in LNCaP cells, with similar amou ts of protein l aded. B) 
qRT-PCR shows robust, specific expression of AR, ETV1 or ERG, with no expression in the 
empty vector-transduced controls. Expression was normalized to ACTB, with mean and SEM 
plotted for biological triplicate samples. Grey bars represent androgen-induced expression and 
white bars represent vehicle control.  
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Figure 3.2: ETV1 and ERG inhibit AR activation of Luciferase reporters
Luciferase reporters driven by hormone response elements were transfected into stable 
RWPE-AR cells to verify AR function. A) Both HRE3-tk-Luc and PSA-Luc are activated by R1881 
stimulation in RWPE-AR cells, but not RWPE-FG9 empty vector control cells. B) Stable overexpression of 
ETV1 or ERG inhibits R1881 induction of both luciferase reporters, as well as baseline activity of PSA-Luc. 
Data are plotted as the ratio of AR-responsive Firefly luciferase activity to activity of the co-transfected 
Renilla luciferase reporter. Mean and SEM are plotted for biological triplicate samples. White, black and 
grey bars represent stable empty vector control, ETV1 or ERG overexpression, respectively.
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Figure 3.2: ETV1 and ERG inhibit AR activation of luciferase reporters in RWPE-1 cells 
 
 Luciferase reporters driven by hormone response elements were transfected into stable 
RWPE-AR cells to verify AR function. A) Both HRE3-tk-Luc and PSA-Luc are activated by 
R1881 stimulation in RWPE-AR cells, but not in the RWPE-FG9 empty vector control. B) 
Stable overexpression of ETV1 or ERG inhibits R1881 induction of both luciferase reporters, as 
well as baseline activi y of PSA-Luc. Data are plotted as the ratio of AR-respons ve Firefly 
lucifer se activity to activity of the c -t ansfected Renilla lucifera e reporter. Mean and SEM are 
plotted for biological triplicate samples. White, black and grey bars represent stable empty vector 
control, ETV1 or ERG expression, respectively. 
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Figure 3.3: ETV1 and ERG enhance AR regulation of endogenous targets
To ask how ETS overexpression affects AR activity at endogenous targets in benign prostate 
cells, stable RWPE-AR-ETV1, RWPE-AR-ERG and RWPE-AR-LACZ control cells were stimulated with 1 
or 10 nM R1881 (light or dark grey bars, respectively) or methanol vehicle (white bars). Expression of the 
androgen-induced genes AQP3 and MME and the AR-repressed gene NT5E was measured by qRT-PCR. 
Expression was normalized to ACTB, with mean and SEM plotted for biological triplicate samples. Both 
ETV1 and ERG enhanced androgen induction or repression, as well as baseline induction or repression, of 
the target genes.
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Figure 3.3: ETV1 and ERG enhance AR regulation of end g ous targets in RWPE-1 cells 
 
 To ask how ETS overexpression affects AR activity at endogenous targets in benign 
prostate cells, stable RWPE-AR-ETV1, RWPE-AR-ERG and RWPE-AR-LACZ control cells 
were stimulated with 1 or 10 nM R1881 (light or dark grey bars, respectively) or methanol 
vehicle (white bars). Expression of the androgen-induced genes AQP3 and MME and the AR-
repressed gene NT5E was measured by qRT-PCR. Expression was normalized to ACTB, with 
mean and SEM plotted for biological triplicate samples. Both ETV1 and ERG enhanced 
androgen induction or repression, as well as baseline induction or repression, of the target genes.  
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Figure 3.4: ETV1 antagonizes AR at a subset of targets in MDA-PCa-2b cells
To address ETV1 effects on AR activity in PCa cells, MDA-PCa-2b cells were transfected 
with siETV1 or siScr and stimulated with 10 nM R1881 or methanol vehicle. ETV1 knockdown was 
quantified with qRT-PCR. Expression of the AR target genes AQP3, NKX3-1, FKBP5, KLK3, TMPRSS2 and 
MME was quantified with qRT-PCR as well. Expression was normalized to GAPDH, with mean and SEM 
plotted for biological triplicate samples. ETV1 knockdown increased androgen induction of AQP3, NKX3-1
and FKBP5, with a trend toward decreased hormone-independent expression of KLK3 and no effect on 
TMPRSS2 or MME.
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Figure 3.4: ETV1 antagonizes AR at a subset of targets in MDA-PCa-2b cells 
  
To address ETV1 effects on AR activity in PCa cells, MDA-PCa-2b cells were 
transfected with siETV1 or siScr and stimulated with 10 nM R1881 or methanol vehicle. ETV1 
knockdown was quantified with qRT-PC . Expression of the AR target genes AQP3, NKX3-1, 
FKBP5, KLK3, TMPRSS2 and MME was quantified with qRT-PCR as well. Expr ssion was 
normalized t  GAPDH, with mean and SEM plotted for biological triplicate samples. ETV1 
knockdown increased androgen induction of AQP3, NKX3-1 and FKBP5, with a trend toward 
decreased hormone-independent expression of KLK3 and no effect on TMPRSS2 or MME.  
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Figure 3.5: ETV1 antagonizes AR in LNCaP cells
The effect of ETV1 knockdown on AR target gene expression was assessed in LNCaP cells. 
A) ETV1 transcript expression in LNCaP cells was measured by qRT-PCR in cells transfected with siScr or 
siETV1, and in untransfected cells. An ETV1 antibody was used to measure protein levels, with GAPDH as 
a loading control. B) LNCaP cells were transfected with siETV1 or siScr and stimulated with 1 or 10 nM 
DHT or methanol vehicle. Expression of the AR target genes KLK3, TMPRSS2, AQP3, NKX3-1 and MME
was quantified by qRT-PCR. In all qRT-PCR, expression was normalized to ACTB. Mean and SEM are 
plotted for biological triplicate samples. ETV1 knockdown increases induction or repression of AR targets, 
suggesting ETV1 inhibition of AR activity.
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Figure 3.5: ETV1 antagonizes AR in LNCaP cells 
 
 The effect of ETV1 knockdown on AR target gene expression was assessed in LNCaP 
cells. A) ETV1 transcript expression in LNCaP cells was measured by qRT-PCR in cells 
transfected w th siScr or s ETV1, and in untransfected cells. An ETV1 antibody was used to 
measure protein lev ls, with G PDH as a loa ing control. B) LNCaP cells were transfected with 
siETV1 or siScr and stimulated with 1 or 10 nM DHT or methanol vehicle. Expression of the AR 
target genes KLK3, TMPRSS2, AQP3, NKX3-1 and MME was quantified by qRT-PCR. In all 
qRT-PCR, expression was normalized to ACTB. Mean and SEM are plotted for biological 
triplicate samples. ETV1 knockdown increases induction or repression of AR targets, suggesting 
ETV1 inhibition of AR activity.  
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Figure 3.6: AKT and PI3K signaling do not alter ETV1-AR interaction in LNCaP cells
To ask whether ETV1 repression of AR was affected by the PTEN signaling pathway, AKT or 
PI3K were inhibited as a proxy for restoring PTEN function. A) Effective AKT knockdown by siRNA 
(siAKT) was validated by Western blot for total AKT and pAKT in duplicate samples. B) siAKT and/or 
siETV1 were transfected vs. siScr, and cells were treated with 1 nM R1881 or vehicle. The AR target genes 
TMPRSS2, FKBP5 and AQP3 were tested by qRT-PCR. Mean and SEM are plotted for biological triplicate 
samples. C) Dose-dependent inhibition of pAKT, but not total AKT, by BEZ235 is verified by Western blot. 
D) Cells were transfected with siETV1 or siScr and treated with 10 nM DHT and/or 500 nM BEZ235. 
Expression of the AR target genes TMPRSS2 and FKBP5 was tested by qRT-PCR. Mean and SEM are 
plotted for biological triplicate samples. In BEZ235-treated cells, ETV1 knockdown reduces DHT induction 
of TMPRSS2 vs. siScr. Otherwise, the effects of ETV1 knockdown or PI3K/pAKT inhibition appear 
independent or additive.
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Figure 3.6: AKT and PI3K signaling do not alter the ETV1-AR interaction in LNCaP cells 
 
 To ask whether ETV1 repression of AR was affected by the PTEN signaling pathway, 
AKT or PI3K were inhibited as a pr xy for restoring PTEN f nction. A) Effective AKT 
knockdo n by siRNA (siAKT) was validated by Wester  blot for total AKT and pAKT in 
duplicate samples. B) siAKT and/or siETV1 were transfected vs. siScr, and cells were treated 
with 1 nM R1881 or vehicle. The AR target genes TMPRSS2, FKBP5 and AQP3 were tested by 
qRT-PCR. Mean and SEM are plotted for biological triplicate samples. C) Dose-dependent 
inhibition of pAKT, but not total AKT, by BEZ235 is verified by Western blot. D) Cells were 
transfected with siETV1 or siScr and treated with 10 nM DHT and/or 500 nM BEZ235. 
Expression of the AR target genes TMPRSS2 and FKBP5 was tested by qRT-PCR. Mean and 
SEM are plotted for biological triplicate samples. In BEZ235-treated cells, ETV1 knockdown 
reduces DHT induction of TMPRSS2 vs. siScr. Otherwise, the effects of ETV1 knockdown or 
PI3K/pAKT inhibition appear independent or additive. 
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Figure 3.7: ETV1 does not alter AR genomic binding or eRNA expression at TMPRSS2 in 
LNCaP cells 
 
  The effect of ETV1 on AR and PolII genomic binding was tested by ChIP. A) A 
screenshot from the UCSC Genome Browser shows AR and ETV1 ChIP-seq peaks as custom 
tracks. Overlapping ETV1 and AR binding sites in the TMPRSS2 -13 kb enhancer, where the 
qPCR primers were targeted, are highlighted in the red box. B) LNCaP cells transfected with 
siScr were stimulated with 10 nM DHT or methanol vehicle to confirm androgen induction. 
Chromatin was immunoprecipitated with antibodies to AR or PolII, or with IgG control. qPCR 
determined enrichment of immunoprecipitated DNA at the TMPRSS2 and PSA (KLK3) 
enhancers relative to the Input. C) As in B, but cells were transfected with siETV1 or siScr and 
stimulated with 1 nM R1881. Chromatin was immunoprecipitated with antibodies to AR, PolII 
or ETV1, or with IgG control. qPCR determined enrichment of immunoprecipitated DNA at the 
TMPRSS2 enhancer and GAPDH TSS relative to the Input. D) qRT-PCR quantified relative 
expression of the TMPRSS2 gene and eRNA transcripts. Expression was normalized to ACTB. 
For all plots, mean and SEM are shown for biological triplicate samples. Neither binding of AR 
or RNA PolII, nor eRNA expression, is significantly affected by ETV1 knockdown.   
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Chapter 4 
 
Conclusion 
 
 This thesis has used in vivo and in vitro models to examine the context-dependent 
interactions of prominent signaling pathways in PCa: AR signaling (genetic variation), ETS gene 
fusions (oncogene activation) and PTEN (tumor suppressor loss). In mice, the interaction of 
strong or weak AR alleles with oncogenic ETV1 was examined alone or in the context of reduced 
expression of Pten, modeling disease course in humans (Figure 1.2). A similar progression was 
modeled in vitro, first examining interactions in benign human prostate cells, then in ETV1
+
 PCa 
cells with or without functional PTEN. Our results suggest that the prognostic value of ETS 
rearrangements or other potential biomarkers may be improved by considering the impact of 
multiple key signaling pathways together. Furthermore, comparison of mouse tumors with 
patient expression data suggests novel roles in PCa of genes associated with other cancers, as 
well as potential ETV1 regulation of known PCa genes. 
 Varying AR strength via Q-tract length does not significantly affect the early neoplasia 
phenotype induced by prostatic ETV1 overexpression in mice. In fact, the overall rate of PIN 
was lower than expected based on a previous study with the same founder ETV1
Tg
 mice (Tomlins 
et al., 2007). It is possible that hAR partially suppresses the ETV1-induced neoplasia, or perhaps 
the mixed C57BL/6-FVB transgenic offspring here were protected relative to the original inbred 
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FVB transgenics. In any case, ETV1 strongly antagonizes AR transcriptional activity in benign 
and early neoplastic prostate tissue. Direct AR targets such as Tmprss2 and Nkx3-1 are 
significantly repressed by ETV1, as are the tumor suppressor Pten and other prostate 
differentiation genes. Despite this strong AR antagonism, prostates of the ETV1
Tg
 mice appear 
grossly normal, while total androgen ablation by castration causes substantial regression of the 
prostate. These results suggest that selective AR antagonism by ETV1, along with a broader 
deprogramming of prostate differentiation genes, can favor proliferation and early neoplasia in 
epithelial cells rather than apoptosis and atrophy.  
 On the Pten
+/-
 background, the striking ETV1 antagonism of AR is largely abrogated and 
fewer genes are differentially expressed in prostates of ETV1
Tg
 mice overall. This may be due to 
greater variance among biological replicate RNA pools than in the first series of mice, perhaps 
reflecting heterogeneity and stochastic variation between individuals, especially as disease 
initiated. There is a general repression of the AR expression program associated with PTEN 
reduction, suggesting that factors downstream of PTEN affect the ETV1-AR interaction as well 
as overall AR activity. A set of 15 genes are significantly upregulated in prostates of ETV1
Tg
 
mice on both backgrounds, suggesting a core set of ETV1-targeted genes. Progression to 
adenocarcinoma occurs in ETV1
Tg
;Pten
+/-
 mice, signifying that the concurrent oncogene 
activation and tumor suppressor loss cooperate in tumorigenesis. Because human patients 
frequently harbor both lesions, clinical studies should determine whether the specific 
combination of ETV1 fusion and PTEN loss is associated with worse prognosis than either single 
alteration. Significant repression of AR-induced genes occurs in the tumors of these mice, 
suggesting that selective AR antagonism by ETV1 is important in early as well as later stages of 
oncogenesis, with repression by PTEN perhaps playing a greater role in intermediate stages. 
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 Additional insights into the relevance of expression changes in ETV1
Tg
 mice to human 
PCa can be attained via the cBioPortal database (www.cbioportal.org). cBioPortal facilitates 
analysis of expression, copy number and mutation data from studies across a variety of cancers, 
including provisional data from The Cancer Genome Atlas (TCGA) (Cerami et al., 2012; Gao et 
al., 2013). Gene sets or individual genes can be queried against the database. KCNN4, SOX4, 
HPN and PSCA, which are upregulated in ETV1
Tg
 mice (Figures 2.7, 2.9), show consistent 
amplification or overexpression across several PCa data sets, including TCGA, as well as across 
a variety of tumor types (Baca et al., 2013; Barbieri et al., 2012; Grasso et al., 2012; Hieronymus 
et al., 2014; Taylor et al., 2010). This suggests that while ETV1 may promote expression of these 
factors, at least in mouse prostate, they may be more generally associated with PCa and other 
cancers as well. LRP8 (Figure 2.9) shows substantial upregulation in one PCa data set (Taylor et 
al., 2010), but a comparable rate of deletion/underexpression vs. amplification/overexpression in 
the provisional TCGA data. This suggests that LRP8 expression may be more sensitive to ETV1 
or other factors, or could potentially have tumor suppressive function in some contexts. Nearly 
500 PCa patient tumors were profiled in TCGA, more than twice the number in the next-largest 
study in cBioPortal, so perhaps a greater breadth of tumor subtypes was represented in the 
TCGA data set. 
 SEMA4G, REC8 and SDF2L1 are among the genes downregulated in prostates and 
tumors of ETV1
Tg
 mice as well as in ETS
+
 PCa patients, and are downregulated in additional 
cancers (Figure 2.9). SEMA4G and REC8 show primarily deletion/downregulation in several 
PCa data sets on cBioPortal (Baca et al., 2013; Grasso et al., 2012; Taylor et al., 2010), yet 
substantial amplification/upregulation in TCGA. SDF2L1 shows consistent 
amplification/upregulation in multiple PCa data sets as well as across several cancer types. This 
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suggests that, as with the ETV1-induced genes, perhaps the expression patterns of SEMA4G and 
REC8 are more broadly represented in the large TCGA set, yet there are distinct PCa subtypes 
where downregulation plays a greater role. Furthermore, perhaps SDF2L1 repression in PCa is 
exquisitely restricted to ETS
+
 tumors. It was identified as such in the Taylor et al. data set 
(Figure 2.9) (Taylor et al., 2010), yet the same study shows an overall upregulation of SDF2L1 in 
PCa vs. normal tissue. Functional analysis of these genes in ETS
+
 vs. ETS
-
 PCa cells, or 
stratification of additional patient data sets by ETS and PTEN status, may be able to shed light 
on these apparent discrepancies. 
 Baena, et al. reported that concurrent ETV1 overexpression was insufficient to promote 
progression to adenocarcinoma in Pten
+/-
 mice, instead promoting only a higher rate of PIN 
(Baena et al., 2013). However, in our hAR;ETV1
Tg
;Pten
+/-
 mice we observed progression to 
adenocarcinoma which was more frequent in hAR
12Q
, including among castrated mice. This 
finding again highlights the interaction between the androgen axis, oncogene activation and 
tumor suppressor loss in mice. In the hAR;TRAMP study, prostate oncogenesis in the hAR
21Q
 
mice was most similar to that in the mAr controls, with hAR
12Q
 and hAR
48Q
 showing the most 
divergent progression (Albertelli et al., 2008). Here, it is possible that a lifetime of increased 
androgen signaling in the hAR
12Q
 mice predisposed them to tumorigenesis following oncogene 
activation (ETV1) combined with tumor suppressor loss (PTEN). Alternatively, given that AR 
and ETV1 can physically interact (Shin et al., 2009), acute dysregulation of shared target genes 
may promote greater oncogenesis with hAR
12Q
 in the Pten-hemizygous background. 
 In vitro, antagonism of AR by ETV1 is observed in benign and malignant cell lines. This 
includes significant repression of the tumor suppressor gene NKX3-1 in MDA-PCa-2b as well as 
LNCaP cells, similar to the repression seen in hAR;ETV1
Tg
 mice and DLP tumors. ETV1 also 
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significantly represses androgen induction of FKBP5 in MDA-PCa-2b cells, with the same trend 
in LNCaP. Decreased FKBP5 would be predicted to increase oncogenic PI3K/AKT activity even 
with intact PTEN signaling (Mulholland et al., 2011). Except for very focal reduction, the Pten
+/-
 
mice in this study retain PTEN protein expression even in tumors, yet also show intense pAKT 
staining. It is possible that reduction of FKBP5 by ETV1 contributes to the increase in pAKT 
levels. The MDA-PCa-2b and LNCaP cell lines both overexpress ETV1 due to genomic 
rearrangement, but the former retains PTEN expression while the latter lacks it. While the 
specific subset of significantly altered AR targets varies slightly between the cell lines, the 
general pattern of ETV1 antagonism of AR regulation is consistent, including antagonism of AR 
activated as well as repressed targets. Furthermore, these results suggest that NKX3-1 and 
FKBP5 are core ETV1-repressed targets across in vivo and in vitro systems. 
 The fact that we saw consistent ETV1 repression of AR in LNCaP cells proved to take up 
a substantial amount of time and resources. The initial goal had been to quickly confirm that 
ETV1 enhanced AR genomic binding and target gene activation (Baena et al., 2013; Chen et al., 
2013; Shin et al., 2009), and then move on to experiments involving additional cofactors. Despite 
knocking down ETV1 in a variety of experimental conditions and with fresh LNCaP cells from 
ATCC, ETV1 was never observed to enhance AR genomic binding or target gene activation (see 
Chapter 3 Discussion). These results highlight the problem of reproducibility between labs, even 
when mirroring experimental samples and protocols as closely as possible. 
 ETV1 and ERG promote similar physiological outcomes, e.g. invasion in vitro and early 
neoplasia in vivo (Hollenhorst et al., 2011a; Tomlins et al., 2007; Tomlins et al., 2008a). 
However, it has been suggested that they do so through divergent gene expression programs, 
with ERG repressing AR and ETV1 cooperating with AR (Baena et al., 2013). In this thesis 
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work, ETV1 repressed key AR target genes in prostates of ETV1
Tg
 mice as well as in tumors. 
ETV1 similarly repressed AR at a number of the same targets in LNCaP and MDA-PCa-2b cells, 
in contrast to reports describing ETV1-AR cooperation in LNCaP (Baena et al., 2013; Shin et al., 
2009). ERG represses AR in LNCaP and additional PCa cell lines (Tomlins et al., 2008a; Yu et 
al., 2010), in line with the behavior observed here for ETV1. In benign prostate cells, both ETV1 
and ERG repressed AR-induced luciferase reporters yet enhanced either activation or repression 
of endogenous AR targets. In a mouse model with ERG overexpression, ERG alone had little 
effect on AR target genes. However, following prostatic deletion of Pten, ERG enhanced 
expression of a panel of AR targets (Chen et al., 2013). Here, antagonism of AR was observed in 
prostates of ETV1
Tg
 mice and in tumors of ETV1
Tg
;Pten
+/-
 mice, but not pre-tumor prostate tissue 
of ETV1
Tg
;Pten
+/-
 mice. However, we did not compare ETV1-negative tumors, and the tumors 
retained at least partial PTEN protein expression, so direct comparison to results with ERG is 
difficult (Chen et al., 2013). The emerging picture from this work and other recent studies is that, 
while by no means identical, molecular actions of ETV1 and ERG may actually be more similar 
than different. It may largely be the cellular context or disease stage that influences their 
differential activity, rather than inherently divergent function, including sensitivity to PTEN 
alterations in vivo. 
 As stated above, overexpression of either ETV1 or ERG repressed AR activation of 
luciferase reporters in benign prostate cells, as expected. However, both ETV1 and ERG 
enhanced activation or repression of endogenous AR targets, even in the absence of androgen. 
RWPE-1 cells lack endogenous AR expression (Altintas et al., 2011). Thus, it is possible that 
they have developed an aberrant epigenetic signature that prevents AR activation of some 
canonical target genes while leaving other genes open to activation (or repression) by a wider 
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variety of transcription factors. AQP3 and MME are expressed in normal tissues, but 
upregulation is associated with several cancers (Chen et al., 2015; Lee et al., 2015). MME was 
initially thought to be a tumor suppressor in PCa based on in vitro behavior and overall reduced 
expression in tumors. However, the subset of patients that retained high MME expression had 
significantly worse survival (Fleischmann et al., 2011; Sumitomo et al., 2005). Similarly, in the 
Prostate Cancer Prevention Trial finasteride lowered the overall rate of PCa yet increased the 
proportion of aggressive tumors and provided no net survival benefit (Thompson et al., 2013). It 
is important to consider molecular subgroups and multiple endpoints when gauging the benefit of 
therapy or the prognostic value of biomarkers. Here, the inappropriate activation of MME and 
AQP3 by ETV1 and ERG in benign prostate cells suggests a potential early role in ETS
+
 PCa. 
 It remains an open question as to whether repression of PSA-Luc or HRE3-tk-Luc by 
ETV1 and ERG in the benign RWPE-1 cells is mediated by inhibition of AR or PolII binding. 
ChIP was attempted with antibodies to these proteins and with qPCR primers spanning known 
AREs represented on the PSA-Luc plasmid (Perez-Stable et al., 2000; Shin et al., 2009). 
Unfortunately, even in hormone-stimulated cells with robust AR activation of the reporter, the 
ChIP signal was not sufficiently above background to be informative. PolII binding at the 
GAPDH transcription start site (TSS), which served as a positive control, confirmed that the 
overall ChIP protocol was successful (data not shown). The PSA-Luc plasmid sequence was 
robustly detected in the Input samples by qPCR, meaning that the plasmid, which is not 
incorporated into the chromosomes, was neither being excessively sonicated nor lost in the lysis 
or wash steps. No-template qPCR reactions showed absence of plasmid contamination. 
Comparison of raw Ct values among targets in the Inputs revealed that the transfected PSA-Luc 
plasmid was present in cells at roughly 1000 times the copy number of genomic loci (data not 
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shown). It is possible that this high copy number could ironically make binding more difficult to 
detect above background, if a minority of copies were bound by AR. Reducing the quantity of 
transfected PSA-Luc plasmid in additional experiments could aid detection of AR and PolII 
binding. 
 It remains controversial whether ETV1 or ERG fusion status alone is a prognostic 
indicator of PCa aggressiveness (Rubin et al., 2011; Taris et al., 2014a). However, ERG staining 
in prostate biopsies is useful in distinguishing HG-PIN and PCa from other histological 
abnormalities. Our mice provide evidence that ETV1 overexpression alone is insufficient for 
aggressive disease, yet cooperation with additional somatic alterations can enhance 
tumorigenesis. Even if ETS
+
 patients do not have worse prognosis, ETS overexpression is still 
likely to be driving prostate tumorigenesis. Among possible PCa drivers, ETS fusions need not 
be significantly worse than other oncogenic pathways to be bona-fide oncogenes. Therefore it is 
still likely to be worthwhile to stratify PCa patients according to ETS fusion status for targeted 
management and treatment. 
 Overall, these experiments highlight the capacity for ETV1 to selectively repress AR 
signaling in vivo as well as in benign and malignant human prostate cells. Consistent ETV1 
inhibition of androgen-induced tumor suppressors and prostate differentiation genes was seen in 
multiple PCa cell lines as well as in mouse prostates and tumors (Higgins et al., 2015). These 
findings support a model in which ETV1 gene fusions, which occur early in PCa, act by initially 
antagonizing tumor suppressor gene expression and maintaining cells in a dedifferentiated state, 
similar to ERG. During disease progression ETV1 cooperates with further tumor suppressor loss 
as well as the androgen axis to promote oncogenesis. 
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Future Directions 
 
 Resistance to therapy continues to be an issue in PCa, even with newer treatment 
strategies. Despite recent improvements in survival, novel therapeutic approaches are still 
needed. This thesis work identified a number of the ETV1-upregulated genes in mice that are 
associated with PCa or other cancers, and can be targeted with small molecules or antibodies in 
vitro or in mouse models. KCNN4, upregulated in BPH and intermediate Gleason grade PCa as 
well as in ETV1
Tg
 mice here, can be targeted with a potassium channel inhibitor (Ohya et al., 
2011). HPN and PSCA are upregulated in ETV1
Tg
 mice and overexpressed in human tumors, and 
have been targeted in model systems as well (Tang et al., 2014; Yu et al., 2013). These targets 
should be tested in xenografts using PCa cell lines overexpressing ETV1. Additionally, recent 
reports have described YK-4-279 as a small molecule inhibitor of ETS oncoprotein activity. 
Initially identified as an inhibitor of the EWS-FLI1 fusion protein in Ewing's sarcoma cells 
(Rahim et al., 2011), YK-4-279 inhibits ETV1 or ERG-driven invasion in vitro along with tumor 
growth in LNCaP (ETV1
+
) xenografts (Rahim et al., 2014). For YK-4-279 as well as the 
previously mentioned compounds, patient-derived tumor xenografts (PDTX) from ETV1
+
 PCa 
patients would be a valuable next step in screening (Malaney et al., 2014). PDTXs from a panel 
of patients would provide greater heterogeneity than the handful of fusion-positive PCa cell lines 
in terms of individual variation, as well as the cellular diversity within a tumor compared to 
relatively homogeneous cell lines. 
 While siRNA knockdown consistently showed that ETV1 represses AR transcriptional 
activity in LNCaP and MDA-PCa-2b cells (Figures 3.4, 3.5, 3.7), neither AR nor PolII genomic 
binding was significantly affected by ETV1 knockdown in LNCaP (Figure 3.7). A remaining 
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hypothesis is that recruitment of additional AR cofactors is inhibited by ETV1. Further ChIP 
experiments to determine whether binding of SRC1, SRC3 or other AR coactivators is affected 
by ETV1 would be informative. Additionally, given that ERG is known to repress AR by 
recruitment of the polycomb repressive complex (PRC) and the placement of repressive 
H3K27me3 histone marks (Yu et al., 2010), ETV1 may act by a similar mechanism. ChIP for 
these proteins and histone marks would reveal whether ETV1 recruits PRC as well. Another 
hypothesis is that while PolII binding at the promoter and enhancer is unaffected by ETV1 
knockdown, ETV1 may inhibit transcription initiation or elongation. ChIP for the histone 
modification H3K36me3, which marks transcriptional elongation (Hon et al., 2009), or for PolII 
further into the gene body, would address this possibility. 
 In some clinical studies, patients positive for the androgen-activated TMPRSS2-ERG 
gene fusion showed more favorable response to abiraterone acetate or orchiectomy (Attard et al., 
2009; Graff et al., 2015). Both treatments target AR signaling and therefore presumably inhibit 
oncogenic ERG expression. However, other studies report no association. In future studies of this 
nature, the patient's AR allele may prove informative as a clinical variable that should be 
considered. Tumors with a TMPRSS2-ERG fusion driven by a stronger AR may be more 
exclusively dependent on androgen signaling and therefore may be more sensitive to abiraterone 
acetate or other inhibitors. Alternatively, TMPRSS2-ERG activation via the stronger AR may be 
better able to persist in spite of hormone therapy. Finally, although ETV1 fusion-positive 
patients are less common than ERG, they still account for 5-10% of PCa, which is equivalent to 
approximately 10,000-20,000 patients per year in the U.S. alone. Prospective studies should 
address the effectiveness of abiraterone acetate and other hormonal therapies against tumors 
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harboring an androgen-induced ETV1 fusion, as well as the wider collection of ETS fusions, 
while considering AR and PTEN status. 
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Table 4.1
cBioPortal gene summary
PCa PCa PCa, 
Metastatic
PCa PCa, CNA 
Study
PCa
Broad/Cornell Broad/Cornell Michigan MSKCC MSKCC TCGA
Nat Gen 2012 Cell 2013 Nat 2012 Can Cell 2010 PNAS 2014 Provisional
ETV1Tg
Mice
ETS+ Local 
PCa
CNA = 109
mRNA = 31 CNA = 56 CNA = 61
CNA = 157 local, 37 met
mRNA = 131 local, 19 met CNA = 104
CNA = 492
mRNA = 487
KCNN4 Up Up x Del: 1 Amp: 1
mRNA (local) up: 20
mRNA (local) down: 5
mRNA (met) up: 4
mRNA (met) down: 3
x
Del: 5
Amp: 1
mRNA up: 20
SOX4 Up Up mRNA up: 1 Del: 1 Del: 1
Amp (met): 1
mRNA (local) up: 49
mRNA (met) up: 14
x
Del: 6
Amp: 2
mRNA up: 14
HPN Up Up mRNA down: 1 x x
mRNA (local) up: 87
mRNA (met) up: 13
mRNA (local) down: 2
x
Del: 3
Amp: 2
mRNA up: 9
PSCA Up Up
Amp: 1
mRNA up: 1
Amp: 1
Del: 1
Amp: 10
Amp (local): 1
Amp (met): 5
mRNA (local) up: 2
mRNA (met) up: 2
Amp: 2
Amp: 26
Del: 3
mRNA up: 8
(1 w/Amp)
LRP8 Up Up mRNA up: 2 x Del: 1
mRNA (local) up: 13
mRNA (met) up: 7
x
Del: 9
Amp: 2
mRNA up: 7
SEMA4G Down Down mRNA up: 1 Del: 1 Del: 4
mRNA (local) up: 2
mRNA (local) down: 4
mRNA (met) down: 2
x
Del: 14
Amp: 1
mRNA up: 11
REC8 Down Down mRNA up: 1 x x
mRNA (local) up: 6
mRNA (local) down: 10
mRNA (met) up: 1
mRNA (met) down: 4
x
Del: 1
mRNA up: 9
SDF2L1 Down Down mRNA up: 1 x Del: 1
mRNA (local) up: 10
mRNA (met) up: 3
x
Del: 4
Amp: 1
mRNA up: 20   
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